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 Introduction ⏐11 
Introduction and outline of the thesis 
The studies described in this thesis focus on components of bone that 
contribute to its resistance to fracture, often referred to as bone quality, in 
patients who are considered at risk for secondary osteoporosis. The objectives 
of these studies were: 
 
1. What is the fracture risk profile in patients at risk for secondary 
osteoporosis, based on clinical risk factors for fractures and parameters of 
bone’s resistance to fracture, including bone mineral density (BMD), 
quantitative ultrasound (QUS), bone turnover markers and morphometry of 
the vertebrae  
2. What is the relation between disease characteristics (including treatment) 
and these parameters of bone’s resistance to fracture  
3. What does follow-up add to the assessment of the fracture risk profile  
 
To this end, studies were performed in patients treated with a suppressive dose 
of levothyroxin because of differentiated thyroid carcinoma, inflammatory bowel 
disease and sarcoidosis. In these patient groups BMD was measured with 
dual-energy X-ray absorptiometry (DXA) and QUS. In addition, the bone 
turnover parameters of resorption, serum carboxy-terminal cross-linked 
telopeptide of type I collagen (ICTP), and formation, serum procollagen type I 
amino-terminal propeptide (PINP), were determined. Clinical risk factors were 
evaluated following a standard questionnaire and disease activity parameters 
according to standard evaluation procedures for each disease. An assessment 
of the prevalence of non-clinical morphometric vertebral factures was done on 
the basis of semiquantitative morphometric analysis of DXA-images of the 
spine.  
 
In chapter 2 general aspects of osteoporosis are summarized as far as relevant 
for the studies performed within the framework of this thesis. Chapter 3, 4 and 
5 describe the observations done in cross sectional studies in patients with 
respectively thyroid carcinoma, inflammatory bowel disease and sarcoidosis. 
Chapter 6 concerns a follow-up study in patients with sarcoidosis to determine 
the effects on BMD and the incidence of morphometric vertebral deformities in 
the course of this condition. Chapter 7 comprises the observations made with 
QUS in patients with inflammatory bowel disease and sarcoidosis and 
discusses the value of this technique in the screening of patients with an 
increased risk for vertebral deformities. This thesis is concluded by a general 
discussion of the main findings of the studies performed and by 
recommendations for further investigations. 
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 Osteoporosis and fracture risk⏐15 
Definition 
Osteoporosis is a skeletal disease characterized by low bone mass and micro 
architectural deterioration resulting in increased bone fragility and hence 
susceptibility to fracture.1 It is a major health problem because of its 
consequent morbidity, mortality and health-care costs. In 1994, an expert panel 
convened by the World Health Organization (WHO) formulated an operational 
definition of the disease for postmenopausal women based on bone mineral 
density (BMD).2 BMD can be expressed as a T-score, the value used for 
diagnosis of osteoporosis, which is a score for the standard deviation (SD) 
above or below the mean value of peak bone mass in young adults. In addition, 
a Z-score is used to compare the patient's BMD to a population of peers (SD 
from the mean BMD of an age-, ethnicity-, and sex-matched reference 
population). In the WHO definition osteoporosis is defined as a T-score of 
≤ -2.5 and osteopenia as a T-score between -1 and -2.5. (Table 2.1).  
 
Table 2.1 Diagnostic criteria for osteoporosis 
T-score value Diagnosis 
Above -1.0 Normal bone 
Below -1.0 and above -2.5 Osteopenia 
Below -2.5 Osteoporosis 
Below -2.5 and at least one fragility fracture Established osteoporosis 
 
This definition of osteoporosis has several limitations. The fracture risk 
increases with decreasing BMD (gradient of risk) and these cut-offs are 
somewhat arbitrary. In addition, this definition was established for 
postmenopausal Caucasian women and may not be applicable to men or 
premenopausal women and people from other ethnic groups. Besides this, 
fractures occur in persons without osteoporosis implicating that bone density is 
not the only determinant of bone’s resistance to fracture. It is nowadays well 
recognized that in particular in minimal trauma fractures bone fragility can be 
due to reduced bone mass as well as changes in the matrix composition and 
microarchitecture of bone. In support of this view, a recent consensus 
conference has defined osteoporosis as ‘a skeletal disorder characterized by 
compromised bone strength leading to an increased risk of fracture’.4 The 
WHO is currently developing algorithms to refine prediction of 5- and 10-year 
fracture risk in the individual patient. These algorithms will be based not only on 
BMD but also on a set of clinical risk factors for fractures that are independent 
of BMD, underscoring the necessity to combine BMD-independent fracture 
assessment with BMD for such predictions.5  
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The magnitude of the problem 
Based on the WHO definition, it has been estimated that 30% of 
postmenopausal Caucasian women in the USA have osteoporosis at the hip, 
lumbar spine or mid-radius, and a further 54% have osteopenia at these sites.6 
Figure 2.1 shows the prevalence of osteoporosis and osteopenia amongst men 
and women in several age groups in the Rotterdam study, a large population-
based cohort study of men and women aged 55 years and over in the 
Netherlands.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Prevalence of osteoporosis in men and women (the Rotterdam Study, 2004). 
 
However, as mentioned before, low BMD alone is not the only determinant for 
an increased fracture risk. In the Rotterdam study the majority of fractures 
occurred in subjects who had a BMD T-score in the osteopenic range.7 In the 
Study of Osteoporotic Fractures (SOF-study), a multicenter, observational 
study of 10000 older women, 74% of women of 65 years and over with a 
fracture did not fulfil the criteria of osteoporosis.8 Eighty-two percent of women 
with a fracture of the distal forearm, hip or spine in the Nordic Research on 
Ageing (NORA) study also had no osteoporosis.9  
Fragility fractures are an important public health issue because of the related 
morbidity and mortality. In white populations, about 50% of women and 20% of 
men older than 50 years will have a fragility fracture in their remaining 
lifetime.6,10 Of the postmenopausal women with recurrent fractures, one out of  
four with a vertebral fracture will have another fracture within one year.11 
Women with a vertebral fracture have a fivefold risk for an other vertebral 
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 Osteoporosis and fracture risk⏐17 
fracture and a twofold risk for a hip fracture. About 6% of women and 11% of 
men die during hospital admission because of a hip fracture.12  
Worldwide, elderly people represent the fastest growing age-group, and the 
yearly number of fractures is therefore likely to rise substantially with continued 
ageing of the population. Thus even if age-adjusted incidence rates for hip 
fractures remain stable, the estimated number of hip fractures worldwide will 
rise from 1.7 million in 1990 to 6.3 million in 2050.13  
Fragility fractures also impose a major economic burden on health-care 
systems worldwide. The combined annual costs of all osteoporotic fractures 
have been estimated to be $20 billion in the USA, about $30 billion in the 
European Union1 and € 210 million in the Netherlands.14  
Clinical fractures 
Most of the clinical fractures are due to a fall. As the risk to fall increases with 
ageing, this is another reason that the incidence of fractures increases with 
age. For vertebral fractures, however, falls play a less important role. The 
majority of vertebral fractures occur during routine daily activities such as lifting 
or changing position, though for many even no triggering activity or event can 
be identified.15 When these fractures come to clinical attention, back pain is the 
most frequent presenting symptom. These fractures may also present with a 
range of other symptoms, including height loss, sleep disturbance, anxiety, 
depression, loss of self esteem, fear of falling, poor appetite and reduced 
quality of life.16,17  
Morphometric vertebral fractures 
Comparison of the incidence of clinically ascertained fractures with the 
estimated incidence derived from a population survey in the community 
indicates that only about one third of women with a vertebral fracture come to 
clinical attention because of lack of typical signs and symptoms of an acute 
fracture.15,18 Radiographic survey of the spine is therefore required to document 
its prevalence and incidence. But even then fractures may be missed, as 
qualitative assessment of fractures from plain radiographs is often overlooked19 
and subject to observer disagreement. For this reason morphometric and semi-
quantitative visual techniques have been developed and are now widely used 
in clinical and epidemiological studies.20,21 Since there is as yet no consensus 
concerning the optimal criteria to determine whether or not a vertebral 
deformity is indeed a fracture, the prevalence and incidence of vertebral 
fractures is still ambiguous and heterogeneous between studies.  
Data from the European Vertebral Osteoporosis Study (EVOS) indicate that 
12% of men and women aged 50-80 years have evidence of a radiographic 
vertebral fracture.22 Prevalence of these fractures increases with age in both 
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men and women. At younger age more fractures can be found in men than in 
women, probably as a result of trauma sustained during previous occupational 
or recreational activity.23 The majority of morphometric vertebral fractures of the 
spine are found in the mid-thoracic area (T7-8) and the thoraco-lumbar junction 
(T12-L1).24 
There are only a few population-based incidence data on vertebral fractures. 
Subjects in EVOS were followed prospectively and the incidence of a 
morphometrically defined vertebral fracture was 10.7/1000 person years in 
women and 5.7/1000 person years in men.25 A similar incidence has been 
reported in the Rotterdam study.26 
Recognition of all vertebral fractures is an important contributor to identifying 
patients at risk for further fractures, as the presence of both clinical and 
morphometric vertebral fractures are strong predictors of fracture risk, 
independent of BMD.27 
Pathophysiology of fractures 
From a mechanical perspective, fractures represent a structural failure of the 
bone, whereby the forces applied to the bone exceed its load-bearing capacity 
(Figure 2.1).28 The forces applied to the bone will depend on the specific 
activity, and will vary with the rate and direction of the applied loads. The load 
bearing capacity of a bone (also referred as ‘whole bone strength’) depends on 
the amount of bone (i.e. mass, size), the spatial distribution of the bone mass 
(i.e. shape and microarchitecture), and the intrinsic properties of the materials 
that comprise the bone.28 Thus, properties at the cellular, matrix, micro- and 
macroarchitectural levels may all impact the mechanical properties of bone.29  
Bone must be stiff, able to resist deformation, so loading is possible. If bone is 
not sufficiently stiff – too flexible for the loads imposed on it – it will deform 
beyond its peak strain and crack. Bone must also be flexible, able to deform to 
allow energy absorption during impact loading. If bone is not sufficiently flexible 
– too brittle – the energy imposed on it will be released by cracking because it 
cannot deform ‘enough’ to absorb it when loaded. Bone must also be light to 
allow movement.30 These seemingly contradictory properties, stiffness yet 
flexibility, and lightness yet strength, are determined by bone’s material 
composition and how this material is fashioned into a three dimensional 
structure.3  
A change in the material or structural components of bone, or the inability of 
bone modelling and remodelling to adapt these material and structural 
properties to the prevailing loads results in bone fragility (Figure 2.2). 
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Figure 2.2 Etiology of age-related fractures and determinants of whole bone strength. 
 
 
Although BMD remains currently the best available non-invasive assessment of 
bone mass in routine clinical practice, many other skeletal characteristics also 
contribute to bone strength. The recognition of these other determinants (often 
referred to as ‘bone quality’) is becoming more important, and their 
incorporation into algorithms of fracture detection remains the subject of 
continuing translational research.31  
The bone mass of an individual in middle age is a result of the peak bone mass 
accrued during intrauterine life, childhood, and puberty, as well as the 
subsequent rate of bone loss. Bone loss takes place as a result of estrogen 
deficiency in postmenopausal women, as well as through estrogen-
independent age-related mechanisms and is furthermore influenced by other 
factors, such as diseases and medications, and than referred to as secondary 
osteoporosis.  
At the cellular level, bone loss occurs because of an imbalance between the 
activity of osteoclasts and osteoblasts. During life, the skeleton is continuously 
remodelled in an orderly sequence of bone resorption followed by bone 
formation – referred to as coupling. If the processes of resorption and formation 
are not matched, there is a remodelling imbalance. This imbalance can be 
magnified by a rise in the rate of initiation of new bone remodelling cycles 
(activation frequency).31 
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Bone remodelling  
Understanding of the cellular basis of remodelling has advanced rapidly in 
recent years. The receptor activator of NFκB (RANK), its ligand (RANKL), and 
the decoy receptor Osteoprotegerin (OPG) are now known to be key regulators 
of osteoclastic bone resorption in vitro and in vivo.32 The bone remodelling is 
initiated on a bone surface usually covered by a very thin layer of 
unmineralized matrix and lining cells. These cells may respond to stimuli (local 
and systemic cytokines, hormones), which initiate the remodelling. The 
differentiation of osteoclasts is stimulated and they start to restore bone. The 
stimulation of osteoclast activity requires an interaction with the osteoblastic 
cells. RANK ligand (RANKL) is expressed and secreted by osteoblast 
precursor cells and binds RANK expressed by osteoclasts, thus promoting the 
differentiation and activity of the osteoclasts. Osteoblasts secrete OPG which 
binds to RANKL and inhibits the RANK-RANKL interaction and thus acts as a 
physiological regulator of bone turnover.3 (Figure 2.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 A schematic overview of the RANKL/RANK/OPG system.33 
 
Osteoblasts and osteoclasts form the bone multicellular unit that reconstructs 
bone in distinct locations. Its purpose in adulthood is to maintain bone strength 
and to be available for adequate calcium homeostasis. In bone, damage due to 
fatigue develops during repeated loading, but only bone has the mechanism to 
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detect the location and magnitude of the damage, remove it, replace it with new 
bone, and then reconstruct the material composition, microarchitecture, and 
macroarchitecture.30 The positive balance in the bone multicellular unit (net 
bone formation) during growth and the negative balance (net bone loss) during 
ageing are small. For these reasons, the rate of gain in bone during growth and 
loss during ageing is driven more by a high remodelling rate than by the 
magnitude of the positive or negative balance in the bone multicellular unit. 
Rapid remodelling is associated with an increased risk of fracture for several 
reasons. First, more densely mineralized bone is removed and replaced with 
younger, less densely mineralized bone, reducing material stiffness.34 As a 
result, bone may become too flexible, bend excessively, and crack under usual 
loading conditions. Second, excavated resorption sites remain temporarily 
unfilled, creating stress concentrators that predispose bone to microdamage. 
Third, increased remodelling impairs isomerization and maturation of collagen, 
which increases the fragility of bone, probably by altering the cross linking 
between adjacent collagen fibrils.35  
Bone remodelling is also influenced in the context of the calcium homeostasis. 
Calcium and vitamin D deficiency result in secondary hyperparathyroidism that 
increases bone remodelling and in variable degrees of mineralization defects, 
that contribute to bone deformities and fractures, such as in rachitis and 
osteomalacia.36 
Recently, important novel genes and pathways for osteoblast differentiation 
and function have been discovered. In particular the identification of the role of 
the low-density lipoprotein receptor–related protein 5 (LRP5) gene in the 
regulation of bone mass is a landmark discovery. LRP5 is a modulator of 
osteoblast function and hence bone formation. It is a co-receptor for a series of 
osteoblast stimulating proteins operating through the Wnt signalling pathway. 
LRP5 is expressed on the osteoblast membrane between two other receptors, 
Frizzled and Kremen. Frizzled and LRP5 bind to Wnt, thereby activating bone 
formation.31  
Last but not least, the central role of the osteocyte, the most frequent bone cell 
type, has been described in the context of signalling towards the osteoblast 
according to mechanical load on the skeleton, yet another pathway to influence 
bone remodelling. Recent discoveries have revealed the complex interaction 
between osteocytes with involvement of prostaglandins, sclerostin and 
Dickkopf.31,37 
Assessment of fracture risk 
Since 1994, the benchmark for the diagnosis of osteoporosis is the assessment 
of BMD. However, as mentioned before, low BMD alone is not the only 
determinant of fracture risk.7 Although it is well established that the risk of 
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future fracture rises with the decline of BMD, it is nowadays evident that 
assessment of fracture risk should encompass all aspects of risk and that 
intervention should not be guided exclusively by results of bone mineral density 
measurements.38 
Clinical risk factors 
The WHO analyzed all international cohort studies in which information of 
clinical risk factors and bone mineral density are available and incident 
fractures have been ascertained.38 On the basis of this information, several risk 
factors independent of bone mineral density have been identified. These 
include history of fracture, glucocorticoid use, family history of fracture, 
cigarette smoking, excessive alcohol consumption, rheumatoid arthritis and low 
body weight.  
For the Dutch Guidelines on Osteoporosis, a clinical fracture risk assessment 
score is developed using the most important risk factors (Relative Risk of at 
least two compared to the general population risk).12 Based on the risk score 
presented in Table 2.2, the individual absolute 10-year fracture risk can be 
calculated. When the risk score is 0, the absolute fracture risk in that part of the 
general population is on average half of that in the total population. With one 
risk factor present, fracture risk is doubled etc.  
 
Table 2.2 Selected risk factors with the estimated associated relative fracture risk (Dutch 
Guidelines on Osteoporosis, 2002). 
Risk factor Fracture risk Risk score points 
Fracture after age 50 years X 2 1 
Prevalent vertebral fracture X 4 2 
Low body weight (<60 kg) X 2 1 
Severe immobility X 2 1 
Corticosteroid use (≥7.5 mg prednisolone daily) X 2 1 
 
Age  
De Laet and co-workers clearly demonstrated that age and BMD are the two 
strongest independent risk factors for future fractures, both vertebral and non-
vertebral and in both men and women.39 The incidence of hip fractures 
increases both with decreasing BMD and with increasing age, and these two 
factors add independently to fracture risk in men and women equally. In 
addition, age can be regarded as a surrogate marker for various other risk 
factors for fractures, such as changes in bone remodelling and bone quality, 
increased tendency of falling, deficient calcium homeostasis and concurrent 
polymorbidity.  
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Methods to determine BMD 
Dual-energy X-ray absorptiometry (DXA) is the most frequently used method 
for BMD measurement and is therefore considered the standard for the 
diagnosis of osteoporosis, the prediction of fractures and the follow-up of 
patients. Other methods to assess BMD are Quantitative Computed 
Tomography (QCT), Single-Energy Absorptiometry (SXA) and Quantitative 
Ultrasound (QUS). Although QCT is probably the best technique to assess 
bone mineral density separately in the trabecular and cortical bone 
compartment, it is not widely used because of lack of data on the predictive 
value for future fracture risk, high cost, limited availability, and, relative to DXA, 
a higher radiation dose needed for measurements.40 
DXA 
Bone density measurements with DXA are effective for predicting fractures in 
clinical practice and are stated to provide a gradient of risk that is as good or 
even better than other commonly used risk stratification measures such as 
blood pressure for stroke and serum cholesterol for cardiovascular disease.41 
The lumbar spine is the most optimal method to study changes in BMD by 
bone loss after menopause or increase in BMD by treatment, as the cell/bone 
ratio is highest in trabecular bone compartments.42 Several studies have, 
however, revealed that with increasing age measurement of the spine is 
increasingly unreliable to document BMD, due to degenerative changes due to 
osteophytes and extra-osseous calcifications.43 The hip represents both 
trabecular (trochanter) and cortical bone (femoral neck) and in a recent study 
hip measurements were found to be superior to the spine in overall 
osteoporotic fracture prediction.44 This study showed that the commonly used 
rule of thumb that fracture rates double for each unit change in T-score clearly 
oversimplifies a more complex situation. The T-score in the hip had a much 
higher predictive value for fracture rates than the spine T-score. E.g. a women 
with spine T-score of -4.0 would be predicted to have only 2.8 times the risk of 
fracture of an otherwise identical woman with spine T-score of 0.0, whereas a 
femoral neck T-score of -4.0 would result in over a 10-fold relative fracture risk. 
Therefore the hip may be preferred as the primary site for diagnosis and 
fracture risk assessment as proposed by others.38,45 
On the other hand, as mentioned earlier, a proportion of fractures occurs in 
patients with osteopenia rather than osteoporosis or even in patients with 
normal BMD.7,8 This is partly due to the fact that BMD measurements by DXA 
reflect some of the components of bone strength, including bone mass, the 
degree of mineralization, and to some extent bone size. However, BMD 
measurements by DXA do not reflect other components of bone strength, 
including the three-dimensional distribution of bone mass, trabecular and 
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cortical microarchitecture, and the intrinsic properties of the bone matrix. To 
quantify these determinants high resolution CT-techniques are necessary. The 
first data of this technique indicate that indeed microarchitectural changes can 
be detected in the absence of osteoporosis.46 The applicability and value of this 
technique over DXA in predicting fracture risk in daily practice is, however, not 
documented yet. 
QUS 
QUS measurements have been proposed as an alternative to BMD 
assessment with DXA.47 Numerous ultrasound parameters used to 
characterize bone have been proposed, including broadband ultrasound 
attenuation (BUA) and speed of sound (SOS). In theory, QUS has the ability to 
provide additional information about bone structure, trabecular orientation and 
microarchitecture that is independent of bone mass and bone mineral 
density.47,48 Moreover, QUS instruments have advantages compared with DXA: 
they are radiation-free, portable, and inexpensive.49 
A number of cross-sectional studies have examined the relationship between 
QUS and fracture. These revealed a lower, an equal, as well as a higher 
prediction value than that obtained with DXA. In the Osteoporosis and 
Ultrasound Study (OPUS), the performance of five QUS devices was compared 
with DXA for discrimination of women with and without osteoporotic vertebral 
fractures. The calcaneus QUS appeared to be as good as axial DXA in 
discriminating women with vertebral fracture.50 
The large prospective longitudinal EPIDOS and SOF studies investigated the 
efficacy of calcaneus QUS to predict fracture risk. The results of these studies 
are close to those obtained in cross-sectional studies. In the EPIDOS study, 
5662 women (median age 80.4 years) were followed for 2 years. The risk of hip 
fractures increased for each SD decrease with BUA by a factor of 2 (1.6-2.4) 
and of 1.7 (1.4-2.1) by SOS. These results are similar to the predictive value of 
BMD after DXA, and remained significant after adjustment for BMD. The 
combination of QUS and BMD appeared not superior to the use of one of them 
alone.51 The SOF study showed that each SD reduction of QUS increases the 
risk of hip (RR 2; CI 1.5-2.7) and vertebral (RR1.3; CI 1.3-1.5) fractures.52 
Methods to determine bone turnover 
Biochemical markers 
Several biochemical markers of bone turnover have been developed. These 
provide non-invasive and fairly inexpensive methods to assess rates of bone 
formation (osteocalcin, bone alkaline phosphatase, peptides of type I 
procollagen) and resorption (deoxypiridinoline and its free and peptide-bound 
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forms such as carboxy-terminal cross-linked telopeptide of type 1 collagen) in 
vivo. However, the precise positioning of these biochemical markers in the 
clinical approach to osteoporosis management has not been established. The 
quality of these measurements has been improved with the introduction of 
automated immunoassay analysers.53 Age, gender, ethnicity, menopausal 
status, disease status, recent fractures, immobility, certain pharmacological 
treatments and circadian variability were shown to influence the levels of bone 
markers.54 55  
Bone turnover markers are mentioned to be of value to study the pathogenesis 
of osteoporosis, predict the risk of future fracture (independently of bone loss), 
and predict and monitor the response to therapy. Prospective studies have 
indeed shown an association between osteoporotic fractures and indices of 
bone turnover independent of bone mineral density in women during the 
menopause and in elderly women.56 In elderly women with values of resorption 
markers exceeding the reference range for premenopausal women, fracture 
risk was shown to be increased about two-fold after adjustment for bone 
mineral density. These findings suggest that a combined approach using bone 
mineral density, clinical risk factors and markers of bone turnover may improve 
fracture prediction.57 
Methods to determine fractures 
Long bone fractures can easily be diagnosed with radiological images made 
after an appropriate trauma and typical clinical picture. This is unfortunately not 
the situation for a substantial number of vertebral fractures. The statement 
“there is no gold standard for the diagnosis or definition of a vertebral fracture” 
is repeated throughout the literature and illustrates the difficulties experienced 
in making a diagnosis of vertebral fracture.58,59 Because a vertebral fracture is 
often unsuspected clinically, the diagnosis of vertebral fracture relies upon 
accurate interpretation of radiological images. Unfortunately, however, 
vertebral fractures are often missed in daily practice. In a large population of 
osteoporotic women recruited in a therapeutic trial, vertebral fractures were not 
adequately reported in the local radiology report in about 30% of patients.60 
The underdiagnosis of vertebral fractures was also evaluated in 934 
hospitalized women who had a lateral chest radiograph. One hundred and 
thirty-two women (14%) were found to have moderate and severe vertebral 
fractures (Grades 2 and 3 according to Genant (Figure 2.4)), but only 50% of 
those were reported in the X-ray report and 23% in the medical report and thus 
treated.19  
Vertebral fractures can be assessed by various methodologies. Radiologists, in 
routine clinical practice, usually visually analyze radiographs of the 
thoracolumbar spine in the lateral projection to identify vertebral fractures 
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(=visual, qualitative technique). While diagnosing the vertebral fracture in 
question, the interpreter also considers the potential differential diagnoses of 
this deformity. Advantages of this technique are detection of anatomic variants, 
detection of non-osteoporotic deformities and detection of technical features 
causing false positives. Disadvantages are inter- and intra-reader variability 
and therefore specific training and expertise is necessary.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Semiquantitative technique of Genant.63 
 
To provide in a more objective parameter, measurements of vertebral 
dimensions are developed and called quantitative technique or vertebral 
morphometry. Melton developed definitions of vertebral fractures utilizing 
percentage reductions in ratios of anterior, middle or posterior heights of 
vertebral bodies compared with normal values for that particular vertebral 
body.18 Eastell modified this method, defining fractures on the basis of standard 
deviation reductions instead of fixed percentages.61 More recently, McCloskey 
proposed a number of modifications to the Eastell/Melton standard criteria 
including the use of predicted posterior heights and the addition of more 
complex criteria.62 Disadvantages of these methodologies are that the 
sensitivity and specificity are very much dependent on thresholds that define 
the prevalent and incident deformity and that there are no corrections for 
anatomical anomalies or other pathologies causing a deformity-like 
appearance.  
In between these two techniques standardized visual assessment has been 
developed, also called semi-quantitative technique. One of these approaches is 
the method of Genant (Figure 2.4), in which the approximate degree of height 
reduction determines the assignment of grades to each vertebra; normal 
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(grade 0), mildly deformed (grade 1; approximately 20-25% reduction in 
anterior, middle and/or posterior height and 10-20% reduction of the projected 
vertebral area; moderately deformed (grade 2; approximately 25-40% reduction 
in heights and 20-40% reduction of the projected vertebral area) and severely 
deformed (grade 3; approximately 40% or greater reduction in heights).63 
There are, however, also limitations of this semiquantitative grading scheme 
that may also apply to other standardized approaches. For example, from 
morphometric data on normal subjects we know that vertebrae in the 
midthoracic spine and in the thoracolumbar junction are slightly more wedged 
than in other regions of the spine. The consequence is that normal variations 
may be misinterpreted as mild vertebral deformities.64 This may falsely 
increase prevalence values for vertebral fractures from visual readings in the 
specific regions.65 The same applies to a lesser extent to the lumbar spine, 
where some degree of biconcavity is frequently seen. However, mild fractures 
detected with this method are also associated with a lower bone density than 
normal, and they also predict future vertebral fractures, although to a lesser 
extent than moderate or severe fractures do.66 
Besides the discussion mentioned above about the different methodologies to 
define a vertebral fracture, there is also no gold standard for interpretation of 
radiographic images. Traditionally vertebral deformities have been identified on 
conventional lateral radiographs of the thoracolumbar spine (morphometric 
radiography or MRX). However, an alternative method of acquiring the lateral 
images of the spine has been developed, which utilizes DXA machines, 
commonly referred to as Morphometric X-ray absorptiometry (MXA) or Instant 
Vertebral Assessment (IVA). This technique has several advantages when 
compared with conventional radiography. These include a significant lower 
radiation dose to the patient, acquisition of a single image of the whole spine, 
fracture assessment can take place at the same time as bone densitometry, 
straightforward supine patient positioning and plan-parallel projection 
minimalising projection deformities.67 However, image quality is less than that 
of the high-resolution conventional radiograph. Previous studies revealed 
nevertheless that this technique enables an accurate and precise 
measurement of vertebral dimensions, despite its moderate image quality.67,68 
This moderate image definition is, however, a significant drawback in 
assessing the upper thoracic region and in distinguishing fracture from other 
anatomical variants. There is good agreement between this technique and 
MRX in identifying fractures when strict criteria for fracture definition are used.69 
Causes of osteoporosis; primary versus secondary forms 
In the majority of patients osteoporosis is a result of bone loss due to the 
menopause and/or ageing. These situations are called primary osteoporosis. 
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Osteoporosis may, however, also be a consequence of certain diseases or 
medications and is then called secondary osteoporosis. Individuals with 
secondary osteoporosis experience bone loss that cannot be explained by the 
menopause or ageing only. The differential diagnosis for conditions and 
medications that contribute to secondary osteoporosis is extensive36 (Table 
2.3). Secondary osteoporosis is common in men and in premenopausal women 
with osteoporosis and in men and women with a recent clinical fracture.70,71 In 
addition, as many as one third of women with postmenopausal osteoporosis 
have identifiable secondary causes that contribute to bone loss.72 Secondary 
causes of osteoporosis in men account for 50-80% of cases of bone loss 
leading to fracture in this population.72 
 
Table 2.3 Main conditions and medications that cause or are risk factors for secondary 
osteoporosis. 
Disorders Medications 
Vitamin D deficiency Heparin 
Primary and secondary hypogonadism Anticonvulsants 
Inflammatory diseases (e.g. inflammatory bowel disease, 
rheumatoid arthritis, sarcoidosis) 
Cyclosporine A 
Gastrectomy Glucocorticoids 
Anorexia Nervosa Lithium 
Malabsorption e.g. Celiac disease Methotrexate 
Hyperparathyroidism  
Cushing syndrome  
Organ transplantation  
Hyperthyroidism  
Epilepsy  
Etcetera  
 
Glucocorticoid-induced osteoporosis 
Glucocorticoid (GC) induced osteoporosis is the most common form of 
osteoporosis caused by medication. GC treatment leads to rapid bone loss and 
impairment of bone quality. GCs adversely affect bone remodelling by both 
reducing bone formation and increasing resorption. GCs have been shown to 
decrease osteoblastogenesis and osteoblast lifespan, and induce osteocyte 
apoptosis. GCs effects on bone resorption most likely result from accelerated 
osteoclast maturation and activity induced by reductions in gonadal and 
adrenal hormones and a negative calcium balance due to reduced 
gastrointestinal absorption of calcium in combination with an increase in urinary 
excretion.73,74 The end result of these changes in bone metabolism induced by 
GCs is an increased fracture risk in patients exposed to these agents. Although 
the estimates of fracture risk on GCs varies, it may be substantial. Van Staa 
and colleagues reported in a meta-analysis an increase of vertebral fracture 
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rate up to fourfold after 3-6 months of therapy with a low dose of GCs (from an 
equivalent of prednisone of ≥2.5 mg daily).75 
Osteoporosis in inflammatory diseases 
It is well known that chronic inflammatory diseases affect bone physiology by 
the production of cytokines.76-78 Inflammation has been shown to drive 
osteoclast differentiation and function by activating the RANK/RANKL (see 
Figure 2.3) pathway. Inflammatory cytokines (including TNF-α) and growth 
factors are shown to promote osteoclastogenesis with subsequent osteoclast-
mediated bone loss. This growing interest in the interaction between 
inflammation and bone has resulted in the emerging field of 
osteoimmunology.79  
 
Osteoporosis in inflammatory bowel disease 
Decreased bone mineral density (BMD) and increased bone turnover are 
frequent findings in inflammatory bowel disease (IBD). On the basis of 
Z-scores, osteopenia can be found in 32 to 38 % of patients with Crohn’s 
disease (CD) and in 23 to 25% of patients with ulcerative colitis (UC). An even 
higher prevalence of decreased bone mass can be found when a T-score is 
used to express changes in BMD.80 
Factors contributing to decreased BMD in IBD patients involve inflammatory 
cytokines, malabsorption due to disease activity or extensive intestinal 
resection, GC use, inability to achieve peak bone mass when the disease starts 
in childhood, malnutrition, immobilization, low body mass index, smoking and 
hypogonadism induced by the chronic inflammatory condition. 
 
Osteoporosis in sarcoidosis 
Sarcoidosis is an inflammatory T-cell driven disease and as a result a 
decreased bone mineral density can be expected in this patient group. Besides 
this, prolonged treatment with GCs and decreased physical activity may also 
negatively affect bone. A limited number of studies on BMD measurements in 
untreated sarcoidosis are published. All these studies are of small size and 
revealed predominantly an unchanged BMD with only mild trabecular bone loss 
in longstanding sarcoidosis.81-83 
Osteoporosis in thyrotoxicosis 
The effects of thyroid hormone on bone metabolism are complex. Overt 
hyperthyroidism is associated with an increased risk of osteoporosis and the 
pathophysiology of it is multifactorial. This includes shortening of the bone 
remodelling cycle and acceleration of bone turnover.84 Thyroid hormone 
indirectly promotes osteoclast formation and activation by inducing the 
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expression of cytokines, prostaglandins and the receptor activator of  NFκB 
ligand (RANKL).85 
A new development has been the discovery of functional thyrotropin (TSH) 
receptors in bone because of the implication that effects that traditionally have 
been attributed to high thyroid hormone levels may be in effect related to low 
TSH levels.86 TSH inhibits RANKL and upregulates OPG thereby inhibiting 
bone loss. In subclinical hyperthyroidism TSH levels are characteristically low, 
resulting in an absence of this block and this can result in bone loss. 
Bone loss is a uniform feature of overt hyperthyroidism. The extent of the 
reduction in bone density in most studies of hyperthyroid patients ranges from 
10 to 20%.87,88 A history of overt hyperthyroidism is a risk factor for hip fracture 
later in life,8,89 and is one of the causes of excess late mortality in previously 
hyperthyroid patients.90 It is therefore reasonable to assume that in some 
hyperthyroid patients bone density does not return to normal after antithyroid 
treatment. Symptomatic bone disease is not a prominent feature of subclinical 
hyperthyroidism. However, mild (subclinical) hyperthyroidism in subjects with 
multinodular goiter was associated with decreased forearm bone density, while 
in postmenopausal women with hyperthyroidism who were treated with 
methimazole a higher bone density of the distal forearm was found compared 
to untreated women.91,92 In addition  the risk of osteoporotic fractures may be  
increased.93  
Prevention of fractures 
Since most fractures occur as a result of falls, attention to reducing the risk of 
falls seems important. Targeted or broad spectrum fall prevention strategies 
have been shown to reduce the risk of falls, but none has shown anti-fracture 
effect. The use of hip protectors reduces the impact of falls on hip fractures in 
high risk individuals if worn at the time of a fall,94 but low compliance remains 
the cause of lack of effect in the daily clinical setting.95  
The drugs used to treat osteoporosis and to decrease fracture risk act on bone 
by manipulating bone turnover in quite different ways. Antiresorptive agents 
decrease bone resorption and bone formation, anabolic agents stimulate bone 
turnover (bone formation more than resorption) and strontium ranelate 
uncouples bone formation (increase) from bone resorption (slight decrease). 
With this classification, antiresorptive treatments include calcium, vitamin D, 
hormone replacement therapy, bisphosphonates, selective estrogen-receptor 
modulators (SERMs), and calcitonin.31,42 The first clearly anabolic therapy that 
stimulates bone formation is recombinant parathyroid hormone (rhPTH).96 
Strontium ranelate has stimulated bone formation and inhibits bone resorption 
in animal models, but the exact anabolic mechanisms on bone formation in 
humans are under investigation.97  
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Whom to treat? 
All clinical guidelines on postmenopausal osteoporosis recommend a case-
finding strategy to identify patients at risk for fractures.98 Patients are identified 
by the presence of well-defined clinical risk factors followed by measurements 
of BMD by DXA. Those with prevalent vertebral fractures or a BMD T-score 
less than -2.5 should receive treatment, although higher intervention thresholds 
have been proposed in the presence of clinical risk factors, such as prevalent 
non-spine fractures and use of glucocorticoids.  
Treatment options 
Many treatments are documented to reduce the risk of fractures in 
postmenopausal women with osteoporosis, including bisphosphonates 
(alendronate, risedronate, ibandronate, zoledronate), SERMs (raloxifene), 
strontium ranelate and rhPTH. However, the anti-fracture profile differs 
between these drugs in terms of spectrum of fractures prevented, speed of 
action in prevention of fractures, duration of the trials, safety, frequency of drug 
intake and compliance.   
Management of secondary osteoporosis 
Dual-energy X-ray absorptiometry is indicated in the initial workup of secondary 
causes of osteoporosis.99 The presence of secondary causes of bone loss may 
further increase the risk of fracture independently of BMD and may necessitate 
earlier pharmacologic intervention. Management of bone loss in inflammatory 
diseases at this time should focus around reduction in inflammation and thus 
on treating the underlying disease.36 Treatment with anti-tumor necrosis factor 
alpha (TNF-α) agents has been shown to reduce progression of juxta-articular 
bone loss in both rheumatoid arthritis and ankylosing spondylitis.100,101 
Treatments directed at preventing the changes in bone metabolism induced by 
GCs are effective, and some have been shown to reduce fracture risk. The 
critical therapies include maintaining adequate calcium and vitamin D stores, 
prevention of falls by strengthening muscles associated with balance and 
ambulation, and bisphosphonates which have been shown to reduce fracture 
risk by 40-90%.102,103 For the prevention and treatment of glucocorticoid 
induced osteoporosis, data are more compelling for bisphosphonates than for 
any other agent.104 
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Abstract 
Background 
Untreated hyperthyroidism and treatment with high doses of thyroid hormone are associated with 
osteoporosis. However, their effect on bone turnover, their contribution to bone mineral density 
(BMD) in the context of other clinical risk factors for osteoporosis and the prevalence of vertebral 
fractures is not well documented.  
 
Methods 
We studied 59 patients receiving L-thyroxine suppressive therapy for differentiated thyroid 
carcinoma (DTC). BMD of the hip was measured by dual X-ray absorptiometry (DXA) and lateral 
DXA pictures of the lumbar and thoracic vertebrae were performed. Bone resorption was measured 
by carboxy-terminal cross-linked telopeptide or type 1 collagen (ICTP) and bone formation by 
procollagen type I amino-terminal propeptide (PINP). Clinical risk factors for osteoporosis  were 
evaluated using a questionnaire.  
 
Results 
Z-scores of BMD were similar as the NHANES (National Health and Nutrition Examination Survey) 
III reference group in women and men, also after long-term (≥10 years) suppression therapy. 
Patients in the lowest and highest quartile of BMD showed significant differences in the presence of 
clinical risk factors. ICTP levels were significantly higher than in age-matched controls, PINP levels 
were not different. We found four patients with a prevalent vertebral deformity. 
 
Conclusions 
We conclude that patients with well-differentiated thyroid carcinoma are not at increased risk of 
developing low bone mass nor have a higher prevalence of vertebral deformities at least when 
treated with relatively low doses of L-thyroxine.  
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Introduction 
Patients with differentiated thyroid carcinoma (DTC) usually have a good 
prognosis and a near normal life expectancy. After initial ablative treatment with 
radioactive iodine these patients are treated with L-thyroxine (L-T4) in relatively 
high doses in order to suppress endogenous thyrotropin (TSH) levels and to 
minimize potential TSH-mediated stimulation of tumor growth.1,2 Adequate 
monitoring of TSH suppression has become possible since the development of 
second and third generation TSH assays.3,4 The degree of TSH lowering 
required to obtain maximal suppression of tumor growth has been subject of 
discussion.5-8 Most recommendations suggest maintaining TSH levels lower 
than 0.1 mU/l1, although in recent guidelines TSH levels between 0.1 and 0.5 
mU/l  are recommended in case there is no residual disease after one year in 
low risk DTC patients.9 Long-term administration of supraphysiological doses of 
L-T4 may have adverse side-effects. In addition to physical discomfort, loss of 
weight, atrial fibrillation and cardiac dysfunction,10,11 the possible negative 
effects on bone mineral density (BMD) and bone remodelling resulting in 
osteopenia and loss of bone strength are an important issue.12 Several 
mechanisms may be involved in the development of osteopenia secondary to 
suppressive therapy with L-T4 such as direct or indirect stimulation of 
osteoclast activity by this hormone. Recently also direct effects of TSH on bone 
remodelling have been described.13 TSH inhibits osteoclast formation and 
survival and also inhibits osteoblast differentiation, and is therefore a negative 
regulator of skeletal remodelling.  
Loss of bone mass is a uniform feature of overt hyperthyroidism; in several 
studies a bone loss of 10-20% has been reported.14-16 A history of overt 
hyperthyroidism is a risk factor for hip fracture later in life,17,18 and is one of the 
causes of excess late mortality in previously hyperthyroid patients.19 
Symptomatic bone disease is not a prominent feature of subclinical 
hyperthyroidism. However, mild (subclinical) hyperthyroidism in subjects with 
multinodular goiter was associated with decreased forearm bone density, while 
in postmenopausal women with hyperthyroidism who were treated with 
methimazole a higher bone density of the distal forearm was found compared 
to untreated women.20,21 In addition  the risk of osteoporotic fractures may be 
increased.22 
Studies in patients with suppressive L-T4 therapy for DTC have generated 
conflicting results. Some authors23-26 found no evidence of lower bone mass in 
this patient group, while others reported more or less deleterious effects on 
bone mass.27-29 In most of these studies numbers were however small, patient 
selection was not well defined and characterization of patients was limited.  
The aim of our study was to evaluate the impact of long-term suppressive 
therapy with L-T4 on BMD in a large cohort of well-characterized patients with 
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DTC, and in the subgroup of patients with suppressive therapy for more than 
10 years. In addition, the prevalence of vertebral deformities was assessed and 
markers of bone formation and resorption were measured in serum. 
Subjects and methods 
Patients 
Between January 2002 and July 2003 all 85 patients with differentiated thyroid 
carcinoma from the outpatient clinic of the University Hospital Maastricht were 
asked to take part in this cross-sectional study. Sixty patients agreed to 
participate. They all had undergone total thyroidectomy and radioactive iodine 
ablation and were taking a suppressive dose of L-T4 (goal of therapy: TSH 
<0.05 mU/l) for a median period of five years (range 1-52 years). In the last six 
months prior to entering this study, TSH-levels were below 0.05 mU/l in 32 
patients and below 0.6 mU/l in the remaining subjects (mean TSH in the total 
group 0.06 mU/l, range <0.05-0.6 mU/l). One patient who had a TSH-level of 
6.1 mU/l was excluded from the study. Therefore complete data are available 
from 59 patients; written informed consent was obtained in all. To affirm that 
this patient group was under continuous suppressive therapy with L-T4 we 
checked serial serum TSH levels in a group of 32 patients with suppressive 
dose of L-T4 for more than five years resulting in a mean TSH of 0.06 mU/l 
(range <0.05-0.35 mU/l).  
The general characteristics of the patients studied are summarized in Table 
3.1. Of the 40 women, 26 were premenopausal and 14 postmenopausal. All 
patients had histologically proven differentiated papillary or follicular thyroid 
cancer. FT4 levels were 21.9±3.3 pmol/l (reference parameter: 8-18 pmol/l) 
and the mean dose of L-T4 therapy was 2.2±0.5 mcg/kg/day. Ten patients used 
a vitamin D analogue and calcium supplementation because of postoperative 
hypoparathyroidism. None of the patients had taken estrogen replacement 
therapy or bisphosphonates.  
Calcium intake of all patients was assessed on the basis of a detailed dietary 
list. Risk factors for osteoporosis as well as daily activities and exercise were 
assessed by a validated questionnaire,30 in which sports, daily and work 
activities are scored with a minimum of zero and a maximum of eighteen. None 
of the 25 patients who declined to participate had impaired mobility or 
symptoms related to vertebral fractures. Mean age of this group was 49 years 
and there were seven postmenopausal women in this group. 
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Table 3.1 Patient characteristics. 
Variable Female Male 
 premenopausal 
n=26 
postmenopausal 
n=14 
 
n=19 
    
Age (years) 40 ± 7 63 ± 9 52 ± 12 
Body mass index (kg/m2) 24.4 ± 3.2 25.5 ± 3.5 28.8 ± 3.2 
Years of suppressive therapy 4 (1-14) 5.5 (1-52) 6 (1-22) 
Postop. hypoparathyroidism 6 1 3 
Dose L-T4 (µ/kg per day) 2.3 ± 0.5 1.9 ± 0.4 2.2 ± 0.5 
Papillary carcinoma 13 8 12 
Follicular carcinoma 10 4 6 
Mixed carcinoma 3 2 1 
Serum FT4 (pmol/l) 22.0 ± 3.2 22.7 ± 3.8 21.1 ± 3.2 
Data are given as mean ± SD, median (range) or numbers if appropriate; Reference parameters: 
serum FT4 8-18 pmol/l; Abbreviations: L-T4, L-thryoxine; FT4, free thyroxine. 
 
BMD and morphometric measurements 
BMD of the hip was measured by dual energy X-ray absorption (DXA, Hologic 
QDR 4500, NHANES-III reference group). The hip was measured in the 
standard projection, and results were reported for femoral neck, trochanter and 
total hip. No data on bone mineral density of the lumbar spine were obtained. 
Standard procedures supplied by the manufacturer for scanning and analysis 
were performed. Calibration with the manufacturer’s spine phantom and quality 
control analysis were performed daily. The coefficient of variation for BMD 
measurements was 1.0%. 
Furthermore after bone density measurements, a lateral single energy 
densitometry of the spine for vertebral fracture assessment was performed. 
This was done by one classified and experienced person with morphometry. 
Anterior, middle and posterior heights were recorded in all vertebrae from T4 to 
L4 (if possible). On the basis of these morphometric measurements prevalent 
vertebral deformity was defined as a reduction of height of 20% or more 
(Genant method31).  
Laboratory assays  
All serum samples were frozen at -20°C immediately after collection. All 
analyses were measured within one badge at the same time to reduce 
variability. Serum TSH was measured using the commercially available 
delayed enhanced Lantanide fluorescence immunometric assay (DELFIA-
method, Perkin Elmer, Wallac, Turku, Finland), measured on an automatic 
immunoanalyser of the same manufacturer. Serum FT4 was measured using a 
commercially available solid phase fluoroimmunoassay (DELFIA-method, 
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Perkin Elmer, Wallac, Turku, Finland); the normal reference range in our 
laboratory is 8-18 pmol/l. As marker for bone formation serum procollagen 
type I amino-terminal propeptide (PINP) was measured and as marker for bone 
resorption serum level of carboxy-terminal cross-linked telopeptide of type I 
collagen (ICTP). PINP and ICTP were determined using commercial RIA kits 
(Orion Diagnostica Oy, Espoo, Finland). For PINP the interassay coefficient of 
variation was 3.2%, the intraassay CV 2.5% and the lowest detectable 
concentration was found to be 0.4 µg/l. For ICTP the interassay CV was 3.5%, 
the intraassay CV 2.3% and the lowest detectable concentration was found to 
be lower than 0.1 µg/l. 
Study samples were compared to serum samples from age and sex-matched 
controls.  
All gave informed consent. None of them were known to have thyroid diseases, 
and all had normal physical examination and normal results of routine lab 
measurements.  
Statistical analysis 
Results are reported as mean ± SD or median and (range) where appropriate. 
T- and Z-scores of the femoral neck, trochanter and total hip (using NHANES-
III) were calculated for the total group, for men, for pre- and postmenopausal 
women, and for a group of patients who received suppressive L-T4 therapy for 
ten years or more. Comparison between groups was done using Student t-test 
with correction for multiple comparisons among groups if the data were 
normally distributed and by Kruskal-Wallis test if the data were not normally 
distributed. Pearson’s correlations were used to calculate the relationship 
between BMD and duration of suppressive therapy. To assess the influence of 
confounding factors on the bone mineral density measurements, a multiple 
regression analysis (stepwise method) was performed with BMD of the total hip 
(Z-score) as a dependent variable and known risk factors for osteoporosis 
(weight below 60 kg, hip fracture mother, fractures in previous medical history, 
postmenopausal state and corticosteroid use), duration of suppressive therapy, 
BMI, calcium intake, physical activity, L-T4 /kg per day, serum FT4, and 
postoperative hypoparathyroidism as independent variables. Another multiple 
regression analysis (stepwise method) was done with BMD Z-scores as 
dependent variable and age, weight, L-T4 /kg per day, serum FT4, number of 
risk factors and physical activity index as independent variables. Patients in the 
highest and lowest quartile of BMD T-scores were compared on presence of 
risk factors with a chi-square test. All analyses were done using SPSS (version 
11.5). A p-value below 0.05 was considered statistically significant. 
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Results 
BMD and general characteristics  
Relative to the background population (NHANES reference group) bone 
mineral density was not decreased in the three study groups (Table 3.2). Five 
patients (two men, three postmenopausal women) had a T-score ≤-2.5 in the 
femoral neck or trochanter and thus met the WHO-criteria for osteoporosis. 
Fifteen patients had suppressive L-T4 therapy for ≥10 years (median 14 yrs, 
range 10-52 yrs). Also in these patients no difference in BMD relative to age-
matched controls (Z-score total hip: median 0.40 (range -1.3–1.4) was 
observed, and no correlation was found between the duration of suppressive 
therapy and BMD of the hip (r=0.01, p=0.91). Moreover we compared the 
group of subjects with TSH levels below 0.05 with the patients who had a 
slightly higher TSH and these groups were similar with regards to T-score and 
Z-score of total hip. BMD of the hip was also not different in patients with or 
without postoperative hypoparathyroidism (Z-score 0.49 versus 0.34), although 
the Z-score of the femoral neck was slightly higher in patients with 
postoperative hypoparathyroidism (0.70 versus 0.05, p=0.029).  
 
Table 3.2  BMD variables. 
 Female Male 
 premenopausal postmenopausal  
 n=26 n=14 n=19 
Z-score    
   total hip 0.44 ± 0.87 0.23 ±1,07 0.37 ± 0.84 
   femoral neck 0.22 ± 0.81 0.12 ± 0.95 0.09 ± 0.93 
   trochanter 0.61 ± 1.10 0.29 ± 1.03 0.49 ± 0.91 
Data are expressed as mean ± SD 
 
 
Data regarding the presence of risk factors for osteoporosis and the daily 
calcium intake and physical activities have been summarized in Table 3.3. The 
activity index had a mean of nearly ten reflecting an average in showing 
activities in this patient group. The calcium intake is with a mean of 807 mg/day 
moderate and insufficient for the postmenopausal group. 
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Table 3.3 Risk factors and questionnaires. 
 Female Male 
 premenopausal postmenopausal  
Number 26 14 19 
Years since menopause  12 ± 10  
Fracture >50 years 0 1 1 
Vertebral fracture 1 1 2 
Hip fracture mother 0 4 1 
Low body weight (<60 kg) 3 5 0 
Immobilisation 0 0 0 
Corticosteroids in last 10 years 0 0 0 
Calcium intake (mg/day) 810 ± 357 782 ± 290 822 ± 326 
Physical activity (Elders) 10.6 ± 4.0 8.6 ± 4.1 9.9 ± 3.6 
Data are given as mean ± SD or number. 
 
Multiple regression analysis, including age, weight, L-T4 /kg per day, serum 
FT4, number of risk factors and physical activity, revealed that higher body 
weight was a significant contributor to BMD of the total hip as expressed as 
Z-score. There were 22 patients with in total 33 known clinical risk factors 
(postmenopausal state, hip fracture mother, vertebral deformity, fracture >50 
year, body weight <60 kg, immobilization and corticosteroid use). Patients in 
the lowest and highest quartile of BMD (T-score of the total hip below -0.70, 
mean -1.4, and above 0.6, mean 1.03) showed  differences in the presence of 
clinical risk factors as earlier defined: in the lowest quartile, eleven of fifteen 
patients had one or more risk factors, in the highest quartile, two of the fifteen 
patients had any risk factor (p=0.001) (Table 3.4). 
 
Table 3.4 Number of patients with clinical risk factors in all 4 quartiles of BMD (T-score of total 
hip). 
 Number of patients in quartile Number of patients with one or 
more clinical risk factor 
T-score ≤ -0.7 15 11 
-0.7 < T-score ≤ 0 15   7 
0 < T-score ≤ 0.5 14   2 
T-score > 0.5 15   2 
 
Markers of bone formation and resorption 
Results of the measurement of markers of bone turnover are summarized in 
Table 3.5. Relative to an age matched control group, ICTP was increased by 
about 25% in all patient groups. PINP levels however, as marker of bone 
formation, did not significantly differ from the control group. Comparing patients 
with and without postoperative hypoparathyroidism, markers of bone formation 
(-44%, p<0.05) and resorption (-7%) were decreased in the 
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hypoparathyroidism group and this resulted in a slightly higher BMD mainly in 
the femoral neck. 
 
Table 3.5 Bone markers total group (in serum in µg/l). 
 Female Male  
 premenopausal controls postmenopausal controls patients controls 
Number 24 24 10 10 19 19 
ICTP (mg/l) 3.8 ± 1.3a 3.0 ± .7 4.4 ± 1.0a 3.3 ± 1.1 4.1 ±. 9a 3.5 ± 7 
PINP (mg/l) 31.0 ± 17.3 28.4 ± 10.1 39.7 ± 21.1 42.8 ± 20.9 36.8 ± 15.5 37.2 ± 11.3 
a p<0.05 vs age matched controls; Abbreviations: ICTP, serum carboxy-terminal cross-linked 
telopeptide of type I collagen; PINP, serum procollagen type I amino-terminal propeptide. 
 
Vertebral deformities 
Fifty-four lateral DXA pictures of the lumbar and thoracic vertebrae were of 
adequate quality for the identification of vertebral deformities, suggestive of 
fracture. Four patients were found to have pre-existing vertebral deformity, i.e. 
7% of patients; two men, one pre- and one postmenopausal woman. These 
patients did not report earlier fractures or pain episodes. All these patients had 
a BMD of the hip within the age-matched reference range (Z-score 0.53±0.91). 
Discussion  
This study demonstrates that long-term suppressive L-T4 therapy in patients 
with DTC does not result in reduced bone mineral density of the hip, neither in 
pre- and postmenopausal women nor in men. BMD, expressed as Z-score, was 
not correlated with duration of L-T4 therapy and even in patients with 
suppressive therapy for more than ten years no significant decrease in BMD 
was found.  
The goal of suppressive L-T4 therapy is to maintain TSH levels <0.05 mU/l with 
a high normal FT4. In our study the dose needed to achieve this level of 
suppression was 2.2 µg/kg of body weight per day, which resulted in FT4 levels 
of 20% above the upper limit of normal. In all studies on this subject in which a 
significant bone loss was observed patients used a 30-50% higher dose of L-T4 
compared to our patients.(27-29, 32, 33) In a cross-sectional study Kung et al. found 
significantly lower BMD in the lumbar spine, femoral neck and trochanter 
(-18%, -12% and -13%) in a group of 34 postmenopausal women, and their 
L-T4 dose was 3.3 µg/kg of body weight per day.28 The same group followed a 
small group of 15 postmenopausal women (3.0 µg L-T4 /kg of body weight per 
day) and found a bone loss of 6.7% in the total hip after two years,32 which 
could be prevented by calcium supplementation (1000 mg/day). Diamond et al 
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demonstrated a negative effect on BMD in both pre- and postmenopausal 
women (n=24)27 with a mean L-T4 dose of 2.8 µg/kg/day and found a 
significant correlation between the total cumulative dose of L-T4 and BMD, 
suggesting that overzealous L-T4 therapy may lead to bone loss. Studies in 
which doses lower than 2.5 µg/kg body weight per day were used, such as the 
more recent study of Rosen et al.24,26,34 did not observe any negative effect on 
BMD. Before the introduction of second and third generation TSH assays in the 
late eighties, it was more difficult to monitor suppressive L-T4 therapy, because 
the detection limit was within the normal range. Therefore dosing of L-T4 could 
not be titrated optimally and was probably unnecessary high. These high L-T4 
doses could affect BMD as was shown in the studies mentioned before. The 
presently available TSH assays are more sensitive and thereby allow better 
dose titration, thereby preventing unwanted loss of BMD. 
The presence of postoperative parathyroid dysfunction could also contribute to 
the low incidence of osteoporosis in our population. PTH is generally thought to 
have a net catabolic effect on bone, including a more pronounced stimulatory 
effect on osteoclast than on osteoblast activity.35 Abugassa et al. found a 
higher bone mass in the proximal femur, lumbar spine and distal radius in a 
group of thirteen patients treated with calcium and/or dihydrotachysterol 
because of postoperative hypoparathyroidism after thyroidectomy for DTC, 
compared to patients with normal parathyroid function after the same surgical 
procedure.36 We also found in the ten subjects with postsurgical 
hypoparathyroidism a significantly higher BMD of the femoral neck. However 
the total hip measurements showed no difference between these two groups, 
and mean Z-scores in the group without hypoparathyroidism were not lower 
than the reference population. 
A total of five patients met the WHO criteria for osteoporosis in the 
measurements of total hip, trochanter or femoral neck BMD. Our risk factor 
analysis indicated that this group could be identified with the known clinical risk 
factors such as postmenopausal state, mother with hip fracture, fracture above 
50 years, immobilization, corticosteroid use and low body weight. 
Although no long-term effect on BMD was found, a significant increase of bone 
resorption as measured by serum levels of carboxy-terminal cross-linked 
telopeptide of type I collagen (ICTP) was observed. The marker of bone 
formation PINP was not altered. Other studies in DTC patients with 
suppressive L-T4 therapy reported an increase in markers of both bone 
formation and resorption. Kung reported increases in hydroxyproline in the 
urine of 130% and osteocalcin levels of 150%28 suggesting increased bone 
turnover. It is not clear why this change in balance between bone formation and 
bone resorption in our patients did not lead to bone loss in the long-term. 
Perhaps the increase in bone resorption is not substantial enough to affect 
BMD. One might also speculate that the compliance with L-T4 therapy might be 
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lower in between hospital visits.37,38 Also a catch-up effect might have occurred 
in the periods of thyroid hormone withdrawal and subsequent hypothyroidism 
for diagnosis or treatment of recurrent or metastatic disease.  
Vertebral fracture is a hallmark of osteoporosis. Only one of the previous 
studies in patients with DTC has evaluated prevalent vertebral fractures in a 
very small group (n=12) and reported no significant difference in the incidence 
of spinal deformities between TSH-suppressed patients and nonsuppressed 
patients.39 We found four patients in this group (7%) with one or more vertebral 
deformities defined as a reduction of 20% or more of the anterior, middle or 
posterior height. In a very large cross-sectional population based study on the 
prevalence of vertebral deformity in European men and women (EVOS) in a 
group of 15570 males and females aged 50-79 years, a prevalent vertebral 
deformity was observed in 12% (range 6-21%).40 We report 7% in a group with 
lower mean age; these patients did not have any clinical sign of vertebral 
fracture nor did they have a lower BMD of the hip. Although the group is small 
we have no indication that the prevalence of vertebral deformity is higher than 
in a European reference population.  
We conclude that L-T4 therapy in doses which suppress TSH just below the 
detection limit of a second generation TSH assay, did not result in significant 
bone loss in our studied population and probably also not in increased fracture 
risk. We suggest that specific screening for osteoporosis in this patient group is 
therefore not recommended, other than on the basis of the known clinical risk 
factors. 
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Abstract 
Background 
Previous studies have documented that the prevalence of decreased bone mineral density (BMD) 
is elevated in patients with inflammatory bowel disease (IBD). The objective of the current study 
was to investigate the prevalence of vertebral deformities in IBD patients and their relation with 
BMD and bone turnover. 
 
Methods 
109 Patients with Crohn’s disease (CD) and 72 with ulcerative colitis (UC) (age 44.5±14.2 year) 
were studied. BMD of the hip (by dual-energy X-ray absorptiometry (DXA)) was measured and a 
lateral single energy densitometry of the spine for assessment of vertebral deformities was 
performed. Serum markers of bone resorption (ICTP) and formation (PINP) were measured and 
determinants of prevalent vertebral deformities were assessed using logistic regression analysis.  
 
Results 
Vertebral deformities were found in 25% of both CD and UC patients. Comparing patients with and 
without vertebral deformities, no significant difference was found between Z- and T-scores of BMD, 
or levels of ICTP and PINP. Using logistic regression analysis the only determinant of any 
morphometric vertebral deformity was gender. The presence of multiple vertebral deformities was 
associated with older age and glucocorticoid use. 
 
Conclusions 
The prevalence of morphometric vertebral deformities is high in CD and UC. Male gender, but 
neither disease activity, bone turnover markers, clinical risk factors, nor BMD predicted their 
presence. The determinants for having more than one vertebral deformity were age and 
glucocorticoid use. This implies that in addition to screening for low BMD, morphometric 
assessment of vertebral deformities is warranted in CD and UC.  
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Introduction 
Decreased bone mineral density (BMD) is a frequent finding in inflammatory 
bowel disease (IBD). Z-scores <-1.0 can be found in 32 to 38% of patients with 
Crohn’s disease (CD) and in about 25% of patients with ulcerative colitis (UC).1 
An even higher prevalence of decreased bone mass can be found when a 
T-score is used to express BMD. Following this approach, we found in a 
previous study osteopenia and osteoporosis in respectively 45 and 13% of 
patients with CD.2  
Specific disease-related factors contributing to decreased BMD in IBD patients 
involve inflammatory cytokines with associated increased bone resorption, 
malabsorption due to disease activity or extensive intestinal resection, 
glucocorticoid (GC) use, inability to achieve peak bone mass when the disease 
starts in childhood, malnutrition and hypogonadism induced by the chronic 
inflammatory condition, and eventually superposed on other clinical risk factors 
such as history of fracture, family history of fractures, immobilization, low BMI, 
smoking and alcohol abuse.1-7 
As a result of the decreased BMD and disease related factors an increased 
overall fracture risk can be expected in patients with IBD.1 In a population-
based cohort study of patients with IBD the incidence rate ratio was 1.4 (95% 
confidence interval (CI): 1.3-1.6) for spine, hip, rib and forearm fractures 
compared to controls, 1.7 (CI: 1.3-2.2) for clinical vertebral fractures and 1.6 
(CI:1.3-2.0) for hip fractures with similar increases for CD and UC.8 In a primary 
care-based case-control study similar increases in the risk of clinical vertebral 
and hip fractures were found in patients with IBD.9 In a large Danish case-
control study a 2.5-fold increase in the risk of symptomatic low energy fractures 
of spine, feet and toes was found among women with CD, but not in men or 
patients with UC.10 In a recent extensive review, Bernstein and Leslie 
concluded that patients with IBD have a moderate increased risk of clinical 
fractures but mentioned a lack of studies on the presence of morphometric 
vertebral fractures and the absence of data in UC.11  
Indeed, the majority of studies on fractures in IBD concern clinical fractures. In 
particular vertebral fractures are however often not clinically recognized and 
can accumulate silently.12 It is well established that a vertebral fracture, clinical 
or morphometric only, is a strong risk factor for subsequent osteoporotic 
fractures, not only at the spine but also at other sites and regardless of 
BMD.13-16 Furthermore, vertebral fracture risk is related to the number and 
severity of prevalent vertebral fractures, while the risk of non-vertebral fractures 
is related to the severity of prevalent morphometric vertebral fractures.16,17 
Data on the prevalence of morphometric vertebral fractures in subjects with 
IBD are scarce. A prevalence of 22% was found on X-rays using a decrease in 
anterior, mid or posterior height of >20 % in a study with 156 patients with CD 
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and osteopenia or osteoporosis, ranging from 20% in patients <20 years old to 
50% in patients older than 60 years.18 In another study a prevalence of 
morphometric vertebral fractures on X-rays (any height loss of >20%) of 14% 
was found (11% in patients <30 years up to 31% in patients older than 60 
years), with no correlation with bone mineral density and use of 
glucocorticoids.19 The prevalence of morphometric vertebral fractures in UC is 
not known.  
For these reasons we investigated in a cohort of 181 subjects with IBD, 
including CD as well as UC patients, the prevalence of morphometric vertebral 
deformities. The findings were related to BMD, bone turnover parameters and 
clinical risk factors to get an impression about the risk of vertebral fractures in 
IBD patients and to what extent this is related to differences in BMD and bone 
turnover. 
Patients and methods 
Patients 
Between January 2002 and July 2003, all patients with inflammatory bowel 
disease who had a disease duration of at least one year, and attended the 
outpatient clinic of the University Hospital Maastricht, were asked to participate 
in this cross-sectional study. Two hundred and two patients (78%) agreed. All 
patients were Caucasians and diagnosed with CD or UC on clinical grounds 
using endoscopic and/or radiological evidence, and by histological investigation 
of mucosal biopsies and/or surgical specimens when available. For 
confirmation of the CD diagnosis the Lennard-Jones criteria20 and for UC the 
Truelove and Witts criteria21 were applied. Sixteen patients with known causes 
of bone mass abnormalities, such as renal failure, thyroid dysfunction, 
alcoholism and ankylosing spondylitis were excluded. None of the other 
patients had any significant co-morbidity. Five patients were excluded because 
of incomplete data. Thus 181 patients were included in this study. This group 
consisted of 81 pre-menopausal women, 26 post-menopausal women, and 74 
men. Demographic, clinical and treatment data of these patients are 
summarized in Table 4.1. The clinical records of all patients were reviewed. 
Age of onset of CD and UC, disease duration and medication use were derived 
from the medical records. Glucocorticoid (GC) use was scored as never, 
previous (stopped more than three months before including in the study) or 
current. If patients were currently using glucocorticoids (GCs) the daily dose 
was noted. Furthermore, current use of other immunosuppressive medication, 
vitamin D and calcium or budenoside use were also recorded. 
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Table 4.1 Demographic, clinical, and treatment variables in the study patients (n=181). 
Variable All 
n=181 
Crohn’s disease
n=109 (60%) 
Ulcerative colitis
n=72 (40%) 
p* 
between 
CD and CU 
Demographic variables     
   Female sex 107 (59) 75 (69) 32 (44)    0.001 
   Postmenopausal 26 (14) 17 (16) 9 (13) ns 
   Age (years) 44.5 ± 14.2 41.9 ± 13.9 48.5 ± 13.8  <0.01 
   Body mass index (kg/m2 ) 25.0 ± 4.2 24.3 ± 4.0 26.0 ± 4.4    0.01 
   Daily dietary calcium intake (mg) 687 ± 360 663 ± 369 723 ± 347 ns 
Clinical variables     
   Disease duration (years) 8 (1-36) 8 (1-36) 9 (1-28) ns 
   1,25(OH)2D3 (nmol/l) 0.13 ± 0.04 0.13 ± 0.04 0.13 ± 0.04 ns 
   CDAI (>150=active disease)  118 ± 88   
   CAI (score 0-21)    5.9 ± 3.5  
   Physical activity index (score 0-18) 8.8 ± 3.6 8.8 ± 3.6 8.7 ± 3.8 ns 
Treatment variables     
   GC use never 40 (22) 19 (17) 21 (29) ns 
   GC use ever 119 (66) 81 (74) 38 (53)  <0.01 
   GC use current 22 (12) 9 (8) 13 (18) ns 
   Current use of bisphosphonates 22 (12) 14 (13) 8 (11) ns 
   Current calcium supplement 56 (31) 44 (40) 12 (17)    0.001 
   Current vitamin D supplement 53 (29) 41 (38) 12 (17)  <0.01 
   Current use of immunosuppressive 
medication 
84 (46) 64 (59) 20 (28)  <0.001 
   Current use of budenoside 54 (30) 46 (42) 8 (11)  <0.001 
   Daily dose GC current group (mg) 6,25 (0-30) 5 (0-30) 10 (0-20) ns 
Clinical risk factors for osteoporosis     
   Fracture >50 years 0 0 0  
   Vertebral deformity by DXA 45 (25) 25 (23) 20 (28) ns 
   Low body weight (<60 kg) 30 (17) 22 (20) 8 (11) ns 
   Low physical activity index ≤5 37 (21) 20 (19) 17 (24) ns 
   Mother with hip deformity 11 (6) 5 (5) 6 (8) ns 
Data are given as mean ± SD, median (range) or number (%) Reference parameters: 1,25(OH)2D3 
0.040-0.200 nmol/l; Abbreviations: 1,25(OH)2D3, 1,25 dihydroxyvitamin D; CDAI, Crohn’s disease 
activity index; CAI, colitis activity index; GC, glucocorticoid; DXA, dual X-ray absorptiometry 
 
Patients were evaluated according to a standard protocol that included 
measurement of height and weight, measurement of bone mineral density 
(BMD) and collection of a blood sample and morning urine.  
Calcium intake of all patients was scored on the basis of a detailed dietary list. 
Known clinical risk factors for osteoporosis (weight below 60 kg, hip fracture in 
the mother, history of fractures after age 50, menopausal status and severe 
immobilization) as well as daily activities and exercise were assessed by a 
validated questionnaire,22 in which sports, daily and work activities are scored 
with a minimum of zero and a maximum of eighteen. Current disease activity in 
CD was evaluated using the Crohn’s Disease activity Index (CDAI)23 and in UC 
the colitis activity index (CAI)24 was applied. Patients with CD were considered 
to have active disease when CDAI was >150. Informed consent was obtained 
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from all participants and this study was approved by the ethical committee of 
the hospital. 
Laboratory assays 
As a marker for bone formation, serum procollagen type I amino-terminal 
propeptide (PINP) was measured. As a marker for bone resorption, serum 
carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) was 
assessed. Both PINP (interassay coefficient of variation (IE-CV) 3.2%, intra-
assay CV (IA-CV) 2.5%, lowest detectable concentration 0.4 µg/l] and ICTP 
(IE-CV 3.5%, IA-CV 2.3%, lowest detectable concentration <0.1 µg/l) were 
measured using commercial RIA kits (Orion Diagnostica Oy, Espoo, Finland). 
The Z-score for these bone markers was obtained using a Dutch reference 
group (300 women, 150 men), checked for normal BMD of the lumbar spine 
and femur and normal 25-hydroxyvitamin-D levels.25 Serum 1,25-dihydroxy-
vitamin D concentration was determined by RIA using a commercially available 
kit (IDS Ltd, Boldon, England, IE-CV 18%, IA-CV 15%). 
Bone Mineral Density and morphometry 
In all 181 patients bone mineral density (BMD) of the hip was measured by 
dual X-ray absorptiometry (DXA, Hologic QDR 4500). As reference group the 
NHANES III database was used. Measurements were done in the standard 
projection, and results were reported for femoral neck and trochanter. Standard 
procedures supplied by the manufacturer for scanning and analyses were 
performed. Calibration with the manufacturer’s spine phantom and quality 
control analysis were performed daily. The coefficient of variation for BMD 
measurements was 1.0%. The number of patients with osteopenia and 
osteoporosis was determined according to the WHO classification in which 
osteopenia is defined as a T-score between -1 and -2.5 and osteoporosis as a 
T-score ≤-2.5. To adjust for age and gender, Z-scores were used. 
Furthermore, after bone density measurement a lateral single energy 
densitometry of the thoracic and lumbar spine for vertebral fracture assessment 
(VFA) was performed (also called Morphometric X-ray absorptiometry 
(MXA)).26 The scans obtained were analyzed twice by one trained operator 
(intra-observer correlation: 0.85), using the semi-quantitative method of 
Genant.27 The observer was blinded to the T-score values and to the values of 
the first set of measurements. After visual examination six points were placed 
on each vertebral body. From these points three vertebral heights were 
measured: anterior (Ha), mid (Hm) and posterior (Hp); On the basis of the 
average score of these morphometric measurements ratios were calculated 
and a prevalent vertebral deformity was defined as a reduction of height of 20% 
or more.27 For crush deformity ratio was calculated by dividing Hp of the 
vertebra with Hp of the vertebra below. Grade 1 (mild) deformity was defined 
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as a reduction of 20 to 25% in any height, grade 2 (moderate) 25 to 40% and 
grade 3 more than 40% (severe). 
Statistics 
Student t-tests, chi-square tests, and one-way ANOVAs were used, depending 
on the variables and subgroups tested. The analyses were performed with 
Z-scores in order to correct for age and gender when comparing (sub)groups. 
One-sample t-tests were used to compare patient scores with norm scores. A 
logistic regression analysis was performed to examine the determinants of 
morphometric vertebral deformities. Sex, age, weight, disease, illness duration, 
CDAI, CAI, physical activity, vitamin D, GC use, current use of vitamin D, 
calcium, immunosuppressive medication, budenoside and hip fracture mother 
were examined as potential determinants. Furthermore, we analysed the risk 
factors for having >1 vertebral deformity. 
Results 
Bone mineral density 
The results of BMD measurements and bone turnover markers are shown in 
Table 4.2. In the total group, osteoporosis was found in 4% of patients and 
osteopenia in 55%. Excluding patients currently using glucocorticoids and/or 
bisphosphonates, the average Z-score of the femoral neck (FN) was decreased 
compared to the reference population (-0.29, CI: -0.45, -0.14; p<0.001). The 
average Z-scores were lower in patients with CD (trochanter:-0.27, CI: -0.45, 
-0.08 and FN: -0.51, CI: -0.70, -0.33) compared with patients with UC 
(trochanter 0.27, CI: 0.00, 0.53 and FN: 0.06, CI: -0.19, 0.31; p=0.001 and 
<0.001, respectively). 
 
Table 4.2 BMD variables and bone turnover markers in IBD patients currently not using 
bisphosphonates and/or glucocorticoids. 
Variable Total group Crohn’s disease Ulcerative colitis p 
between CD and CU 
 n=143 n=88 n=55  
   Z-score     
   Femoral neck  -0.29 ± 0.94*  -0.51 ± 0.89*  0.06 ± 0.93 <0.001 
   Trochanter  -0.06 ± 0.94  -0.27 ± 0.86*  0.27 ± 0.98  0.001 
Bone markers in serum     
   ICTP (µg/l)  3.6 ± 1.3  3.7 ± 1.3  3.5 ± 1.2 ns 
   Z-score ICTP  0.49 ± 1.6*  0.53 ± 1.3*  0.41 ± 1.6 ns 
   PINP (µg/l)  48.7 ± 27.5  50.9 ± 26.0  45.1 ± 29.8 ns 
   Z-score PINP  0.59 ± 1.6*  0.69 ± 1.6*  0.42 ± 1.7 ns 
Data are given as mean ± SD; * p<0.05 versus 0 for Z-scores; Abbreviations: ICTP, carboxy-
terminal cross-linked telopeptide of type I collagen; PINP, procollagen type I amino-terminal 
propeptide. 
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Patients who never used glucocorticoids (n=40) had normal Z-scores of FN 
and trochanter compared with patients with previous or current use of this 
medication who had lower BMD values (respectively: -0.07, CI: -0.35, 0.22 
versus -0.52, CI:-0.68, -0.37; p<0.01 and 0.17, CI: -0.08, 0.42 versus -0.31, CI: 
-0.47, -0.15; p<0.01). 
Bone turnover parameters 
In the total group of patients currently not on bisphosphonates and/or 
glucocorticoids the average Z-score for ICTP (Z-ICTP) was increased 
compared with the reference population (0.49, CI: 0.22, 0.76; p<0.001), as well 
as the marker of bone formation (Z-PINP) (0.59, CI: 0.31, 0.86; p<0.001). This 
was especially observed in patients with CD (Z-ICTP: 0.53, CI: 0.19, 0.88; 
p<0.01, and Z-PINP: 0.69, CI: 0.36, 1.03; p<0.001 respectively). 
Morphometric vertebral deformities 
Vertebral deformities (ratio of <0.80) were found in 77 vertebrae of 45 patients 
(25% of total group). This prevalence was similar in both subgroups of patients. 
Fifty-nine of the deformities were wedge deformities, 16 biconcave and two 
crush deformities. Fifty one were mildly deformed, 22 moderate and four 
severe deformations were seen. With regard to the localization of the 
deformities (Table 4.3), prevalence peaks were found in the low thoracic 
region. Seventeen patients (age 51.5±17.0 years) had more than one vertebral 
deformity. This group consisted of eleven men, three premenopausal and three 
postmenopausal women. The majority of these patients (82%) was current or 
previous glucocorticoid user. Comparing the groups with and without vertebral 
deformities, no significant difference was found between Z- or T-scores of BMD 
of the trochanter or femoral neck, nor in Z-ICTP, or Z-PINP (Table 4.4, Figure 
4.1). The two differences between these groups were an older age (p<0.05) 
and more males (p<0.01) in the group with deformities. Furthermore, no 
differences were seen between the two subgroups in current use of calcium 
and/or vitamin D supplements, aminosalicylates, immunosuppressive 
medication and budenoside. Logistic regression analysis revealed that the only 
determinant of prevalent morphometric vertebral deformity was sex (OR: 2.25, 
p<0.05, CI: 1.11, 4.54), indicating that men have a more than twofold higher 
chance of morphometric vertebral deformity. In addition, the only determinants 
for having more than one vertebral deformity were age (OR: 1.05, p=0.02, CI: 
1.05-1.09) and current GC use (OR: 4.98, p=0.01, CI: 1.42, 17.49).  
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Table 4.3 Distribution of the number of vertebral deformities and rating of their severity. 
 Number of deformities Mild deformity Moderate deformity Severe deformity 
T4     
T5     
T6  5  3  2  
T7  1  1   
T8  4  2  2  
T9  6  5  1  
T10  7  5  2  
T11  23  15  7  1 
T12  19  12  5  2 
L1  5  4  1  
L2  3  1  1  1 
L3  2  1  1  
L4  2  2   
L5     
 
 
Table 4.4 Patients with morphometric vertebral deformity (n=45) versus without morphometric 
vertebral deformity (n=136).  
Variable Without vertebral 
deformity 
With vertebral 
deformity 
p* 
Z-score    
   Femoral neck  -0.40 ± 0.96  -0.49 ± 0.93 ns 
   Trochanter  -0.19 ± 1.01  -0.27 ± 0.75 ns 
T-score    
   Femoral neck  -0.95 ± 0.91  -1.22 ± 0.88 ns 
   Trochanter  -0.45 ± 0.96  -0.63 ± 0.78 ns 
Bone markers in serum    
   Z-score ICTP  0.58 ± 1.8  0.75 ± 1.8 ns 
   Z-score PINP  0.72 ± 2.4  0.34 ± 1.6 ns 
Demographic and patient variables     
   Males 48 (35) 26 (58) <0.01 
   Postmenopausal women 19 (14) 7 (16) ns 
   Crohn’s disease/Ulcerative colitis 84/52 25/20 ns 
   GC use, never  30 (22) 10 (22) ns 
   GC use, previous 90 (66) 29 (65) ns 
   GC use, current 16 (12) 6 (13) ns 
   Disease duration (years) 8 (1-36) 8 (1-34) ns 
   Age (years)  43.3 ± 13.6  48.2 ± 15.2 <0.05 
   Body mass index (kg/m2)  24.9 ± 4.4  25.3 ± 3.8 ns 
   CDAI (>150=active disease)  120 ± 89  110 ± 84 ns 
   CAI (score 0-21)  5.9 ± 3.3  5.9 ± 4.0 ns 
   Physical activity index (score 0-18)   8.6 ± 3.6  9.3 ± 3.8 ns 
   Calcium intake (mg)  691 ± 366  674 ± 345 ns 
Data are given as mean ± SD, median (range) or number (%). * p between patients with and 
without vertebral deformity; Abbreviations: ICTP, carboxy-terminal cross-linked telopeptide of type I 
collagen; PINP, procollagen type I amino-terminal propeptide; GC, glucocorticoid; CDAI, Crohn’s 
disease activity index; CAI, colitis activity index. 
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Figure 4.1 Number of patients with and without a vertebral deformity.  
 Abbreviations: UC, ulcerative colitis; CD, Crohn’s disease  
Discussion  
In our series of patients with IBD we found vertebral deformities with 
quantitative morphometric X-ray absorptiometry (MXA) in 25% of patients. This 
high prevalence is remarkable as the majority of our patients was relatively 
young and premenopausal.  
Our observations of an increased prevalence of morphometric vertebral 
deformities are in line with the few clinical studies reported on vertebral 
deformities in CD. Stockbrügger and co-workers found on X-rays a prevalence 
of 14% in a younger population with CD and this increased to 43% in female 
patients above 60 years.19 In another study in 156 patients with CD and 
osteopenia and osteoporosis, a prevalence of 22% of vertebral deformities was 
found.28 Other studies also revealed an increased risk for clinical vertebral 
fractures in both CD and UC.8,9,29 Our finding of a preferential localization of 
vertebral fractures at the mid and lower thoracic spine is also in line with earlier 
findings.19 In addition, an increase of morphometric vertebral deformities similar 
to CD was found in UC, which has not been reported in the literature before. 
To what extent the high prevalence of vertebral deformities in IBD differs from 
subjects without IBD is uncertain, as no data on non-clinical deformities in 
healthy young and premenopausal individuals are available. The best 
comparison with healthy subjects for the present study stems from the EVOS 
study, in which in a very large cross-sectional population based study 
European subjects aged 50 to 79 years were investigated. The prevalence of 
vertebral deformities on X-rays in this study was 12% (range 6-21%) in males 
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and females.30 The Rotterdam study, in which 3469 men and women aged 55 
years and older were studied, revealed a prevalence of vertebral deformity 
suggestive of fracture in 6.9% of men and 7.5% of women.31 In a previous 
study on 60 subjects (mean age 49±13 years), who were followed after initial 
successful treatment for differentiated thyroid carcinoma, we found vertebral 
deformities in 7%.32 All these data support the fact that IBD is a relevant risk 
factor for vertebral deformity suggestive for fracture. 
For the determination of vertebral fractures a variety of morphometric 
approaches can be used. These different approaches can result in slightly 
different outcomes.27,33-35 Compared with subjective qualitative assessment, 
quantitative morphometry is a more reproducible method for assessing 
vertebral deformity and therefore these approaches are often used in 
conjunction. As, however, a gold standard for vertebral fracture is not available, 
it is still not clear which method is the most appropriate to establish vertebral 
deformities and on the basis of that to determine the occurrence of vertebral 
fractures. We followed the method of Genant,27 which is based on a reduction 
of the ratios of anterior, middle or posterior heights. This is the simplest and 
most practical method.36 It is also the method used in the majority of studies on 
IBD patients published18 and an association with future fracture risk is 
documented.37 The above mentioned EVOS study, however, applied the 
methodology described by McCloskey and Eastell and co-workers in which 
measurements are corrected for normal variations in vertebral shape.35 
Relative to the method of Genant, the method of Eastell may result in a lower 
prevalence of vertebral deformities. In our series, use of the method of Eastell 
resulted in vertebral deformities in 20% of patients (data not shown), which is 
indeed lower than the prevalence found after the method of Genant, but still 
indicates a substantial prevalence in this young population.  
We used MXA instead of standard spine radiographs for morphometric 
determination of vertebral deformities. Several studies have documented that 
MXA is comparable to standard spine radiographs for this approach.38-41 MXA, 
also called VFA (vertebral fracture assessment with DXA), has several 
advantages over vertebral morphometry on conventional spinal radiographs 
(MRX). The radiation dose is much lower (<80µSv) and assessment of BMD 
and vertebral deformities can be combined. Although MXA is thus an 
established technology to detect vertebral fractures and to identify patients 
likely to benefit from pharmacological therapy who otherwise might not be 
treated,42 this technology has some limitations as well. These include limited 
ability to provide a differential diagnosis for the detected deformities, lower 
sensitivity for milder fractures and inability to evaluate the uppermost thoracic 
levels. However, its negative predictive value is high.17 Other disorders that 
may cause changes in vertebral shape involve congenital abnormalities and 
conditions as severe osteoarthritis43 and Scheuermann’s disease. We have, 
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however, no indications that these relatively rare conditions may have 
interfered with our observations. On the other hand, vertebrae in the mid-
thoracic spine and thoraco-lumbar junction are slightly more wedged than in 
other regions of the spine34,44 and, as a result, normal variations may be 
misinterpreted as mild vertebral deformities.45,46 This may have contributed to 
overestimation of vertebral deformities in our series, although we feel only to a 
limited extent. 
The occurrence of vertebral deformities in our series was equally distributed 
between subjects with a normal and osteopenic BMD at the hip. Only a few 
subjects had osteoporosis according to the WHO criteria, even when patients 
on bisphosphonates were included. BMD of patients with vertebral deformities 
was not different from the other patients studied. These findings are in line with 
other studies.19 In one of these studies, bone mass and fracture risk was 
determined and revealed a reduced BMD of the lumbar spine in patients with 
vertebral fractures compared with those without (T-score -2.50±0.88 versus 
-2.07±0.66; p<0.05), but also no relevant differences of BMD at the hip.18 This 
is in line with the many observations that indicate that low BMD is only one of 
the components that determines fracture risk and that most fractures,47 whether 
clinical or morphometric, occur in patients without osteoporosis in terms of a 
T-score ≤-2.5.47 Therefore, our results support the current trend towards 
identifying patients at risk for fracture even when BMD is normal7 as reflected in 
the current WHO initiative to develop refined models for fracture prediction in 
the individual patient.47 The clinical consequence of our findings is that a more 
systematic search for vertebral deformities is warranted in CD and UC, as 
suggested by others.11 
It is well known that chronic inflammatory diseases affect bone physiology by 
the production of cytokines48,49 such as interleukin-6 and 17, tumour necrosis 
factor, the RANKL/OPG balance and the Wnt signalling pathway, probably 
mainly by an influence on bone turnover.50-52 We indeed found an increase in 
bone turnover parameters in both groups of patients, which was more 
pronounced in CD than in UC. In postmenopausal women, the level of bone 
turnover has been shown to be as strong a predictor of fractures as the level of 
BMD and independent of low BMD.53,54 This may be due to an effect of 
increased bone turnover on bone microarchitecture, in particular a loss of 
horizontal trabeculae not reflected in a change of BMD but nevertheless 
associated with an increased bone fragility and thus fracture risk. This may 
imply that changes in microarchitecture of bone rather than changes in BMD 
are involved in the occurrence of vertebral deformities in IBD and that vertebral 
deformities are therefore a better reflection of bone failure than low BMD. An 
alternative explanation may be that vertebral deformities in IBD occur during 
phases of active disease and increased bone turnover and bone loss, with 
subsequent recovery of bone during improvement of the IBD condition 
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obscuring the relation of BMD with fracture. This is however unlikely, as we 
found no relation between vertebral deformities and current disease activity. 
In our study, male gender was a determinant for having a vertebral deformity. 
In a previous study were men with CD at greatest risk for osteoporosis,55 but no 
gender difference was shown in studies on fracture risk. Age was the 
determinant for having more than one vertebral deformity as it is a determinant 
in most epidemiological studies on fracture risk in healthy subjects.56,57 This 
was also found in a study of 218 patients with CD in which follow-up data at 20 
years were compared with those of age- and gender matched controls. An 
overall risk ratio of 2.2 for a thoraco-lumbar fracture was calculated in this study 
with IBD and age as the only determinant and not use of glucocorticoids or 
intestinal resections.58 In another study, GC use per se appeared also not to be 
an important risk factor for fractures in IBD, although this study showed an 
increased fracture risk in CD but not in UC after long term use of GCs.10 We 
found that patients with current use of glucocorticoids had a higher prevalence 
of multiple (>1) vertebral deformities. This is in line with the view that long term 
use of GCs is an independent risk factor for fracture.59 
Limitations of our study are the cross-sectional design and the lack of an age 
and sex matched control population. Another limitation is the measurement of 
BMD in the hip only. This may have been contributed to an underestimation of 
osteopenia as it can not be excluded that more influence of BMD on risk of 
non-clinical vertebral fractures would have been found if DXA of the spine was 
also performed. However, as measurement of the hip allows measurement of 
both trabecular and cortical bone, a recent study shows that for this reason hip 
measurements may be superior to the spine in overall fracture prediction.60 
In conclusion, we performed a large cross-sectional outpatient-based study on 
patients with Crohn’s disease and ulcerative colitis and have demonstrated that 
in patients with these conditions the prevalence of non-clinical vertebral 
deformities suggestive of vertebral fractures is substantial, even in patients with 
normal BMD. Disease activity, glucocorticoid therapy and known risk factors for 
fracture appear to be poor predictors for the occurrence of these asymptomatic 
vertebral deformities, although GC use predicted the presence of multiple 
deformities. This implies that in addition to screening for osteoporosis by 
means of a bone mineral density measurement, morphometric assessment of 
vertebral deformities is warranted in IBD as well. As a vertebral fracture is a 
strong predictor of a new fracture of the spine or at other sites, one may 
wonder whether the high prevalence of vertebral deformities in IBD is a reason 
for preventive treatment as it is recommended for subjects with increased 
fracture risk, such as subjects who are treated with supraphysiological doses of 
glucocorticoids. To support this hypothesis, prospective follow-up data on the 
development of vertebral deformities in patients with inflammatory bowel 
disease are needed. 
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Abstract 
Background 
Sarcoidosis is a chronic inflammatory T-cell-driven disease that can also affect bone. We evaluated 
bone remodelling and bone mineral density (BMD) in patients with sarcoidosis and their 
dependency of disease-related and treatment-related factors. 
 
Methods 
In 124 patients BMD of the hip (DXA) and markers of bone resorption (ICTP) and formation (PINP) 
were evaluated. Furthermore a lateral DXA of the spine for morphometric assessment of vertebral 
deformities was performed in 87 patients. Potential predictors of bone markers, BMD and 
determinants of prevalent vertebral deformities were assessed using multiple and logistic 
regression analysis.  
 
Results 
The population studied comprised untreated patients (n=51), patients that previously used 
glucocorticoids (n=31) and patients currently using glucocorticoids (n=42). In all these groups the 
age- and gender corrected Z-scores of the hip were normal, except in untreated patients, which 
revealed an increased Z-score at the trochanter (p=0.004). In all but the patients currently on 
glucocorticoids the Z-scores for PINP and ICTP were increased (p<0.05). In patients currently on 
glucocorticoids the Z-ICTP was also increased (p<0.05), but the Z-PINP decreased (p<0.01 
compared to untreated patients). In 20.6% of patients one or more morphometric vertebral 
deformities were found.  
 
Conclusions 
Hip BMD is normal in patients with sarcoidosis, despite an increased bone turnover. This may 
imply that in sarcoidosis mechanisms are involved that compensate for the well-known effects of 
cytokines in inflammatory diseases on osteoclastogenesis and bone resorption. Nonetheless, 
vertebral deformities suggestive of fracture were found in a significant number of patients which 
indicates that patients with sarcoidosis still have a relevant fracture risk. 
Thesis Caroline Heijckmann v05.p70   70 18-10-2007   8:53:40
 Bone turnover and BMD in sarcoidosis⏐71 
Introduction 
Sarcoidosis is a multiorgan, inflammatory, granulomatous disorder of unknown 
origin that can affect almost any organ of the body, including bone.1-5 In 
addition to localized bone lesions of sarcoid granulomas,6 increased bone 
mineral density (BMD)7 as well as generalized bone loss have been described 
in longstanding sarcoidosis.8  
There are a number of mechanisms that may be involved in bone changes in 
sarcoidosis. Due to overproduction of 1,25 dihydroxyvitamin D (1,25(OH)2D3) 
by sarcoid granulomas, intestinal absorption of calcium is enhanced and bone 
turnover can be increased.5,9 As sarcoidosis is a chronic T-cell-driven 
inflammatory disease, cytokines such as interleukin 6 (IL-6) and tumour 
necrosis factor are increased. These cytokines play a pivotal role in the 
pathogenesis of granulomatous diseases,10,11 and can also influence bone 
turnover.12,13 Finally, prolonged treatment with glucocorticoids and decreased 
physical activity may also negatively affect bone.  
Up till now, only a limited number of studies on BMD measurements in 
untreated sarcoidosis are published.7,14,15 All these studies are of small size 
and reveal predominantly an unchanged BMD with only mild trabecular bone 
loss in longstanding sarcoidosis.14 This is in contrast with what can be 
expected in a chronic inflammatory disorder. In addition, in only one study bone 
turnover parameters were determined16 and no data are available of fracture 
risk in patients with sarcoidosis. For that reason we studied a large and well-
characterized sarcoidosis population, consisting of a group of untreated 
subjects, subjects that were previously treated with glucocorticoids and 
subjects that were currently on glucocorticoids.  In addition to measurement of 
bone turnover parameters and BMD, morphometry of the spine was done to 
identify vertebral deformities suggestive of non-clinical fractures and to 
substantiate the fracture risk in sarcoidosis. 
Patients and methods 
Patients 
Between January 2002 and July 2003, all 167 sarcoidosis patients with a 
disease duration of at least one year attending the outpatient clinic of the 
Sarcoidosis Management Center of the University Hospital Maastricht, were 
asked to participate in this cross-sectional study. Hundred and thirty-eight 
patients (82%) agreed to participate. All patients were Caucasians and 
diagnosed with sarcoidosis according to the WASOG guidelines,1 based on 
consistent clinical features and results of an analysis of bronchoalveolar lavage 
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fluid.17 In 71% a biopsy confirmed the diagnosis. None of the patients had any 
significant co-morbidity. Known causes of bone mass abnormalities, such as 
renal failure, thyroid dysfunction, alcoholism and long-term anticoagulant use 
were exclusion criteria, but no patient was excluded on the basis of these 
factors. Fourteen patients were excluded because of the use of 
bisphosphonates or hormone replacement therapy. Finally, 124 patients were 
included in this study. This group consisted of 43 pre-menopausal women, 19 
post-menopausal women, and 62 men. The patients were grouped according 
to the way of treatment, e.g. no treatment, previously treated with 
glucocorticoids and currently on glucocorticoids. 
The clinical records of all patients were reviewed. Demographic, clinical and 
treatment data of these patients are summarized in Table 5.1. Patients were 
evaluated according to a standard protocol that included questionnaires related 
to risk factors for osteoporosis, calcium intake, physical activity and health 
status, measurement of height and weight, lung function, measurement of 
BMD, and collection of a blood sample and morning urine. Informed consent 
was obtained from all participants and this study was approved by the medical 
ethics committee. None of the patients who declined to participate or were 
excluded had impaired mobility or a history of vertebral fractures. Mean age of 
this group was 43 years and there were seven postmenopausal women in this 
group. 
Pulmonary evaluation 
Lung function, including forced expiratory volume in one second (FEV1) and 
forced vital capacity (FVC), was measured with a pneumotachograph. The 
diffusion capacity for carbon monoxide (DLCO) was measured using the single-
breath method (both Masterlab, Jaeger, Würzburg, Germany). Values were 
expressed as a percentage of those predicted.18 
Chest radiographs were graded according to the radiographic staging of 
DeRemee (0 to III), adding stage IV, the end stage of lung fibrosis.1,19 All 
interpretations were made by a radiologist who was blinded to the patient’s 
history. 
Bone Mineral Density  
In all 124 patients bone mineral density (BMD) of the hip was measured by 
dual X-ray absorptiometry (DXA) (Hologic QDR 4500). As reference group the 
NHANES III database was used. A standard protocol as described previously 
was used for measurement of BMD.20 Furthermore a lateral DXA of the 
thoracic and lumbar spine for assessment of vertebral fractures (morphometric 
X-ray absorptiometry (MXA))21 was performed in 87 patients. All these 
morphometric analyses were done twice by one trained operator using the 
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quantitative technique of Genant.22 On the basis of the average score of these 
morphometric measurements prevalent vertebral deformity suggestive of 
fracture was defined as a reduction of height of 20% or more.22 
 
Table 5.1 Demographic, clinical, and treatment variables in the study patients (n=124). 
Variable Never GC use 
(n=51) 
Previous GC use 
(n=31) 
Current GC use 
(n=42) 
pa pb 
Demographic variables      
   Female sex 36 (71) 13 (39) 14 (33) <0.001 <0.001 
   Postmenopausal (% of group) 8 (16) 4 (13) 7 (17)   
   Age years 42 (20-67) 45 (25-66) 49 (28-70)   
   Body mass index (kg/m2) 26.9 ± 5.9 26.6 ± 4.8 27.4 ± 5.8   
   Smoking 8 (16) 3 (10) 5 (12)   
   Daily dietary calcium intake (mg) 736 ± 355 880 ± 549 750 ± 347   
Clinical variables      
   Disease duration, median (range) yrs 3 (1-39) 4 (1-20) 3,5 (1-36)   
   Chest X-ray stage (0-I-II-III-IV) 15/10/16/10/0 6/4/9/9/3 4/6/9/16/7  0.002 
   FEV1 (% of predicted ± SD) 98 ± 15 83 ± 24 77 ± 25 <0.001 <0.001 
   DLCO (% of predicted ± SD) 93 ± 14 79 ± 16 77 ± 21 <0.001 <0.001 
Laboratory values (in serum)      
   Calcium (mmol/l) 2.4 ± 0.1 2.4 ± 0.2 2.4 ± 0.1   
   1,25(OH)2D3 (nmol/l) 0.16 ± 0.05 0.14 ± 0.03 0.15 ± 0.04   
   ACE (U/l) 21.4 ± 7.9 21.5 ± 11.2 26.5 ± 13.9   
   sIL-2R (kU/l) 695 (216-2636) 638 (264-4546) 715 (188-4315)   
   Hs-CRP (mg/l) 2.3 (0.2-79) 3.4 (0.2-58) 4.4 (0.2-191)   
Treatment variables      
   Lifetime glucocorticoid dose (mg) - 7200 (200-54000) 13125 (1650-189000)   
   Daily dose (mg) - 17.4 ± 7.9 18.1 ± 9.0   
Clinical risk factors for osteoporosis      
   Fracture >50 years 0 1 of 11 (9) 2 of 20 (10)   
   Vertebral fracture by DXA 8 of 36 (22) 4 of 19 (21) 6 of 32 (19)   
   Low body weight (<60 kg) 8 (16) 4 (13) 2 (5)   
   Severe immobilization 0 0 0   
   Low physical activity index ≤5 10 (20) 9 (29) 17 (41)   
   Mother with hip fracture 2 (4) 1(3) 3 (7)   
Data are given as mean ± SD, median (range) or number (%); Reference parameters: Calcium: 2.1-2.6 mmol/l; 1,25(OH)2D3 0.040-
0.200 nmol/l; ACE: 9-25 U/l; sIL-2R: 241-846 KU/l; hs-CRP: 0-10 mg/l; Abbreviations:  GC, glucocorticoid; FEV1, forced expiratory 
volume in one second; DLCO, diffusion capacity for carbon monoxide; 1,25(OH)2D3, 1,25 dihydroxyvitamin D; ACE, angiotensin 
converting enzyme; sIL-2R, soluble interleukin-2 receptor; Hs-CRP, high-sensitivity C-reactive protein. a p value never GC use 
versus previous + current; b p value never versus current 
Laboratory assays 
As a marker for bone formation, serum procollagen type I amino-terminal 
propeptide (PINP) was measured. As a marker for bone resorption, serum 
carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) was 
assessed. Both PINP [interassay coefficient of variation (IE-CV) 3.2%, intra-
assay CV (IA-CV) 2.5%, lowest detectable concentration 0.4 µg/l] and ICTP 
(IE-CV 3.5%, IA-CV 2.3%, lowest detectable concentration <0.1 µg/l) were 
measured using commercial RIA kits (Orion Diagnostica Oy, Espoo, Finland). 
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The Z-score for these bone markers was obtained using a Dutch reference 
group (300 women, 150 men), checked for normal BMD of the lumbar spine 
and femur and normal 25-hydroxyvitamin-D levels.23 Serum 1,25-dihydroxy-
vitamin D concentration was determined by radioimmuno-assay using a 
commercially available kit (IDS Ltd, Boldon, England, IE-CV 18%, IA-CV 15%). 
High-sensitivity C-reactive protein (hs-CRP) was measured by particle-
enhanced immunonephelometry on the BN Prospec (Dade Behring). The 
detection limit is 0.175 mg/l and the measuring range is 0.175-1100 mg/l. 
Soluble IL-2 receptor (sIL-2R) was determined on the IMMULITE automated 
analyzer, by means of a two–site chemiluminescent enzyme immunometric 
assay with a measuring range of 50-7500 kU/l (Diagnostic Product Corporation, 
Los Angeles, CA, cat no LKIP1). Serum angiotensin converting enzyme (ACE) 
was measured using a colorimetric method. The precision of the ACE assay 
was <5.6% and the reference interval for ACE was 9-25 U/l. 
Questionnaires  
Known clinical risk factors for osteoporosis were evaluated (weight below 60 
kg, hip fracture in the mother, history of fractures after age 50, menopausal 
status, severe immobilization and use of glucocorticoids) and physical activity 
was scored on a scale between 0 and 18.24 Calcium intake was evaluated via 
an extensive dietary list and dosing and duration of glucocorticoid therapy was 
evaluated by means of a patient questionnaire and verified using all the records 
of the patient’s pharmacist. 
Statistics  
Student t-tests, chi-square tests, and one-way ANOVAs were used, depending 
on the variables and subgroups tested. Z-score analyses were performed to 
correct for age and gender when comparing subgroups. One-sample t-tests 
were used to compare patient scores with norm scores. Z-scores for BMD were 
evaluated by univariate analysis in relation to risk factors and clinical variables 
using bivariate correlations for continuous and ANOVA for dichotomous 
variables. Bone markers were expressed as Z-scores. Factors associated 
(p<0.10) with a low BMD and bone turnover were entered as independent 
variables in a multiple regression analysis (method: stepwise) with BMD and 
bone turnover as outcome measures. A logistic regression analysis (method: 
enter) was performed to examine the determinants of morphometric vertebral 
deformities. For the comparison of subgroups with various glucocorticoid 
status, a Bonferroni correction was applied, resulting in a p<0.002 being 
considered significant. For the remaining analyses, the level of significance 
was set at p<0.05. 
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Results 
Bone Mineral Density  
The results of BMD measurements are shown in Table 5.2 and Figure 5.1. In 
all groups the Z-scores of the hip were normal, except the Z-scores of patients 
that never used glucocorticoids, which revealed an increased Z-score at the 
trochanter (0.45, 95% confidence interval (CI): 0.15- 0.76, p=0.004, Figure 5.1). 
This Z-score was also higher than that of subjects using glucocorticoids when 
the data of patients currently on glucocorticoids were taken together with 
patients that previously used glucocorticoids (0.01 (CI: 0.06- 0.84), p<0.05, not 
shown in figure).  
 
Table 5.2 BMD variables and bone markers. 
Variable Never GC use 
(n=51) 
Previous GC use 
(n=31) 
Current GC use 
(n=42) 
BMD (gm/cm2)    
   Femoral neck 0.84 ± 0.13 0.79 ± 0.09 0.80 ± 0.18 
   Trochanter 0.76 ± 0.12 0.71 ± 0.10 0.71 ± 0.18 
Z-score    
   Femoral neck 0.1 ± 1.2 -0.4 ± 0.9 0.0 ± 1.0 
   Trochanter 0.5 ± 1.1a -0.1 ± 1.0 0.1 ± 1.1 
T-score    
   Femoral neck -0.5 ± 1.2a -1.1 ± 0.9a -0.8 ± 1.0a 
   Trochanter 0.1 ± 1.1 -0.4 ± 0.9a -0.3 ± 1.0 
Bone markers in serum    
   ICTP (µg/l) 4.1 ± 1.6 4.4 ± 1.7 3.7 ± 1.5 
   Z-score ICTP 1.2 ± 2.0a 1.3 ± 1.9a 0.7 ± 2.0a 
   PINP (µg/l) 43.8 ± 19.7 42.9 ± 19.7 35.6 ± 20.4 
   Z-score PINP 0.4 ± 1.1a 0.3 ± 1.4 -0.4 ± 1.3 
Data are given as mean ± SD; a p value <0.05 one-sample t-test compared to norm scores; 
Abbreviations: BMD, bone mineral density, ICTP, carboxy-terminal cross-linked telopeptide of type 
I collagen; PINP, procollagen type I amino-terminal propeptide. 
 
Multiple regression analysis, including factors that correlated in the univariate 
analysis, revealed only a positive relation between the Z-scores of the femoral 
neck and trochanter with body mass index (BMI). Z-scores for BMD were 
unrelated to 1,25(OH)2D3, radiographic stage of sarcoidosis (0/I versus II/III/IV), 
lifetime glucocorticoid dose, daily glucocorticoid dose, and duration of 
glucocorticoid use. In the subgroups we found nevertheless a significant 
negative correlation in the current glucocorticoid users between Z-score at the 
trochanter and 1,25(OH)2D3 (r=-0.38, p=0.02) and between Z-score at the 
femoral neck and this vitamin D (r=-0.35, p=0.03). The Z-scores for BMD were 
furthermore also unrelated to life-style factors (smoking, physical activity and 
calcium intake) or to a family history of osteoporosis. There was also no 
relation between physical activity scores and BMD.  
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Figure 5.1 Z-scores (± SD)  in the untreated group (n=51) versus current glucocorticoid users 
(n=42); Abbreviations: ICTP, carboxy-terminal cross-linked telopeptide of type I 
collagen; PINP, procollagen type I amino-terminal propeptide; GC, glucocorticoid. 
Bone turnover parameters 
ICTP and PINP levels and their Z-scores for the different groups are shown in 
Table 5.2 and Figure 5.1. Z-scores for ICTP (Z-ICTP) as well as PINP (Z-PINP) 
were increased in the group of patients not using glucocorticoids (1.2 (CI: 0.6, 
1.8), p<0.001 and 0.4 (CI: 0.0, 0.7, p<0.05 respectively). In the group of 
patients currently on glucocorticoids the Z-ICTP was also increased (0.7 (CI: 
0.0-1.3), p=0.05), but the Z-PINP decreased (-0.4 (CI: –0.8, 0.0), p<0.01 
compared to glucocorticoid naïve patients). 
Z-ICTP was positively related to sIL-2R (r=0.22, p<0.05), ACE (r=0.26, p<0.01), 
and negatively to DLCO (r=-0.21, p<0.05) and these correlations were even 
stronger in patients with current glucocorticoid use (r=0.57 (p<0.001), 0.42 
(p=0.009) and -0.46 (p=0.005) respectively). The Z-PINP revealed no relation 
with these parameters. Bone turnover parameters were also not related to 
BMD, 1.25(OH)2D3 values or fracture rate. 
Clinical fractures and vertebral deformities 
Three symptomatic, non-vertebral fractures were found in patients older than 
50 years (3 out of 51 patients, 6%), one of which appeared to be a fracture of 
the thumb due to a sarcoid granuloma. When the fracture occurred,  these 
patients suffered from sarcoidosis for eight, 22 and 23 years, respectively. In 
18 out of the 87 (20.6%) patients of which DXA images were available for 
morphometric analysis one or more vertebral deformities (24 vertebrae in total) 
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were found. None of these had been symptomatic. All but one of the 
deformities revealed a mild or moderate vertebral height loss of less than 40%. 
When comparing the group with and without vertebral deformities (threshold 
value of one of the ratios of <0.8), no significant difference was found between 
Z-scores of BMD of the trochanter or femoral neck, nor in Z-ICTP or PINP. 
Using T-scores, a lower BMD at the femoral neck was found in subjects with 
vertebral deformities compared to those without deformities (-1.2 (CI: -1.5, -0.9) 
and -0.3 (CI: -0.6, -0.1), p=0.001). The BMD at the trochanter was not different. 
Furthermore, the group with deformities appeared to be older (42 years (CI: 40, 
45) versus 52 years (CI: 48, 56), p=0.001) and contained more males (p=0.01). 
No differences were seen in other clinical risk factors, glucocorticoid use, daily 
glucocorticoid dose and disease duration.  
Logistic regression analysis revealed that higher T-score for femoral neck was 
associated with a lower prevalence of vertebral deformities (OR=0.225 (CI: 
0.083-0.607), p=0.003). In addition, determinants of higher prevalence of these 
deformities were male gender (OR=6.34 (CI: 1.355-32.518), p=0.020) and 
older age (OR=1.120 (CI: 1.039-1.206)). 
Discussion  
In our series of a large group of sarcoidosis patients the BMD measured with 
DXA at the hip was not different from the reference population, even if currently 
or previously treated with glucocorticoids. Surprisingly, in untreated patients the 
BMD at the trochanter appeared even increased. As sarcoidosis is a T-cell 
driven disease one would expect a decreased BMD, like in other inflammatory 
conditions.25 Our observations are, however, in line with the few clinical studies 
reported on BMD in sarcoidosis.7,14,15 Tervonen et al.7 reported in 14 patients 
with a disease duration of less than two years an increased BMD. Two other 
studies of small size involve BMD in untreated patients.14,15 These studies also 
found a normal BMD relative to age and sex-matched controls, except for five 
postmenopausal women in which the BMD was moderately decreased at the 
spine in longstanding sarcoidosis only. 
In contrast to a normal BMD, untreated patients had increased values for the 
bone resorption marker ICTP and the bone formation marker PINP, which is 
suggestive of increased bone turnover.  
In patients currently on glucocorticoids the bone resorption marker ICTP was 
also increased, although slightly less than in subjects not using glucocorticoids. 
PINP, however, was decreased in these patients. As this is in line with the well 
known effects of glucocorticoids on bone turnover,26,27 one would expect in 
such a situation a decreased BMD as well. This discrepancy and the finding of 
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a normal BMD in untreated patients in spite of increased bone turnover is 
suggestive of a protective effect of sarcoidosis on bone metabolism.  
It is well known that chronic inflammatory diseases affect bone physiology by 
the production of cytokines.28,29 Cytokines enhance RANKL expression in 
osteoblasts. RANKL is the receptor activator of the nuclear receptor-κB ligand 
that induces osteoclast differentiation by binding to the receptor activator of the 
nuclear factor-κB (RANK) on the surface of osteoclasts. In addition, cytokines 
involved in chronic inflammatory diseases can suppress osteoprotegerin (OPG) 
expression in osteoblasts. OPG is a decoy receptor for RANKL and prevents 
binding of RANKL to its osteoclast receptor and thereby inhibits osteoclast 
differentiation. Although there are no data on changes in the RANKL/OPG ratio 
in sarcoidosis, enhanced activation of nuclear receptor kappa beta (NF-κB), the 
downstream transcription factor of this pathway, has been reported previously 
in patients with sarcoidosis.30,31 The consequence of the influence of cytokines 
on bone mass in chronic inflammation is usually increased bone resorption 
rather than increased bone formation,25 which contrasts with our finding of 
normal BMD in sarcoidosis. Recent data, however, indicate that a cytokine as 
interleukin-6 may influence osteoblast proliferation and differentiation as well.32 
It may well be that these dual functions of cytokines on bone physiology are 
responsible for the normal BMD in untreated sarcoid subjects, despite 
increased bone turnover. 
We found a positive relation between sIL-2R and ACE and the bone resorption 
marker ICTP, but not between the bone formation marker PINP. No relation 
was found between hs-CRP and bone turnover markers. All these factors can 
be used as markers for disease activity in sarcoidosis. Of these, in particular 
sIL-2R is suitable to monitor the activity of the T-cell component in 
sarcoidosis.33,34 Studies on circulating hs-CRP in several immune and 
inflammatory diseases have shown that increased levels of this parameter are 
associated with decreased BMD.35 Our finding of no such an association and a 
positive relation of sIL-2R and ACE with ICTP but without consequent decrease 
of BMD supports our suggestion that in sarcoidosis a dual mechanism different 
from other chronic inflammatory conditions is involved in bone metabolism. 
One of the factors responsible for this possible dual mechanism in sarcoidosis 
may be vitamin D. Vitamin D receptors are identified on macrophages and 
activated T-lymphocytes,36 which is suggestive for a potential role for vitamin D 
in regulating the immune system. Sarcoid granulomas can induce production of 
the active compound of vitamin D, 1,25(OH)2D3.5,9 Several studies have shown 
that this hormone can regulate osteoblastogenesis and osteoclastogenesis, the 
latter partly via regulation of the OPG and RANKL expression of osteoblasts.37 
As we found no differences of 1,25(OH)2D3 levels between the groups of 
patients studied besides a weak negative correlation in the current 
glucocorticoid users with Z-scores of BMD and no relation with bone turnover 
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parameters, our findings are not indicative for such an influence of vitamin D on 
bone turnover on sarcoidosis, neither precludes such an effect. 
As fracture risk is not only determined by loss of bone mass, but also by loss of 
bone micro architecture and consequent bone strength,38,39 a BMD not different 
from a reference population does not preclude increased fracture risk. In our 
series, only three clinical fractures were observed. With quantitative 
morphometric X-ray absorptiometry (MXA), however, vertebral deformities, 
which may be suggestive of vertebral fractures, were found in 21% of the 87 
patients studied. It is uncertain whether or not this prevalence differs from 
subjects without sarcoidosis, as no data on non-clinical deformities in healthy 
young and premenopausal individuals are available. The best comparison with 
healthy subjects for the present study stems from the EVOS (European 
Vertebral Osteoporosis Study) study, in which in a very large cross-sectional 
population based study European subjects aged 50 to 79 years were 
investigated. The prevalence of vertebral deformities on X-rays in this study 
was 12% (range 6-21%) in males and females.40 The investigators of this study 
used the methodology of McCloskey and Eastell and co-workers.41,42 Following 
this methodology measurements are corrected for normal variations in 
vertebral shape. Relative to the more simple and practical method of Genant 
we used,43 the method of Eastell may result in lower prevalences of vertebral 
deformities. Presumably, the prevalence of vertebral deformities we found in 
patients with sarcoidosis is not different or perhaps slightly more than what can 
be found in a reference population. To what extent these vertebral deformities 
are indeed related to vertebral fractures is ambiguous too in the absence of a 
gold standard, but may implicate that the occurrence of non-clinical vertebral 
fractures in patients with sarcoidosis is not rare despite a normal BMD.  
One of the limitations of our study is the cross-sectional design. Longitudinal 
studies are necessary to determine whether or not sarcoidosis may result in 
substantial bone loss on long term, despite the protective mechanisms 
suggested before. Another limitation is the measurement of BMD at the hip 
only, although recently was demonstrated that hip measurements were 
superior to the spine in overall fracture prediction.44 This may have contributed 
to an underestimation of osteopenia and it can not be excluded that more 
differences would have been found if DXA of the spine was also performed. 
Despite this drawback of the study, we found an even increased BMD of the 
trabecular bone of the trochanter in untreated patients. Therefore, it is highly 
unlikely that measuring the BMD of the trabecular bone of the spine would 
have revealed a decreased BMD compared to the reference population. In 
addition, the morphometric assessment of vertebral fractures in a subset of 
patients may have underestimated the prevalence of fractures as well. 
In conclusion, we found that in patients with sarcoidosis hip BMD is normal, 
even if currently or previously treated with glucocorticoid, despite an increased 
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bone turnover. As the increased bone resorption was found to be related to 
ACE and sIL-2R, we suggest that this is - at least partly - the result of disease 
activity. The increased bone formation, which apparently neutralizes the 
increased bone resorption, may imply that in sarcoidosis mechanisms are 
involved that compensate for the well-known effects of cytokines in 
inflammatory diseases on osteoclastogenesis and bone resorption. 
Nonetheless, vertebral deformities suggestive of fracture were found in a 
significant number of patients which indicates that patients with sarcoidosis still 
have a relevant fracture risk. 
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Abstract 
Background 
Previous studies from our group have shown that morphometric vertebral deformities suggestive of 
fractures can be found in 20% of patients with sarcoidosis, despite a normal bone mineral density 
(BMD). The aim of this study was to determine the incidence of new and/or progressive vertebral 
deformities and the evolution of BMD during the course of this disease. 
 
Methods 
BMD of the hip (DXA) and vertebral fracture assessment (VFA) with lateral single energy 
densitometry was performed at baseline and after 45 months (range 35-49) in 66 patients with 
sarcoidosis. In addition, clinical risk factors and glucocorticoid use were assessed. Potential 
predictors of new and/or progressive vertebral deformities were assessed using logistic regression 
analysis. 
 
Results 
The BMD of the total group was unchanged after follow-up, even in the groups with current or 
previous glucocorticoid use. The prevalence of vertebral deformities increased from 20 to 32% 
p<0.05) of all subjects, and in 17 subjects (26%) one or more new or progressive vertebral 
deformities were diagnosed. Logistic regression analysis revealed that a lower T-score of the 
femoral neck at baseline (OR=2.5 (CI: 1.0-5.9), p<0.05) and a mother with a hip fracture (OR=14.1 
(CI:1.4-142.6), p<0.05) were determinants of new and/or progressive vertebral deformities. 
 
Conclusions 
Our study shows that in subjects with sarcoidosis the number of vertebral deformities increases in 
the course of  this disease, despite unchanged BMD. The combination of a low normal BMD and a 
family history of fragility fractures confers an increased risk of the incidence of these deformities. 
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Introduction 
Sarcoidosis is a T-cell driven chronic inflammatory disease. Although chronic 
inflammation has been associated with decreased bone mineral density as a 
result of the effects of cytokines on bone metabolism,1-4 we and others could 
not demonstrate changes in BMD in subjects with this condition, even if treated 
with glucocorticoids (GCs). In a cross-sectional study of 124 subjects with 
sarcoidosis, BMD values similar to an age- and sex-matched reference 
population were found.5 Comparable observations were made in three small 
studies in untreated patients.6-8 These studies also found a normal BMD 
relative to age and sex-matched controls, except for a small group of 
postmenopausal women in which BMD was moderately decreased at the spine 
in longstanding sarcoidosis only.7  
Although in our cross-sectional study normal BMD values were observed, 
increased levels of the bone resorption marker serum carboxy-terminal cross-
linked telopeptide of type I collagen (ICTP) and the bone formation marker 
serum procollagen type I amino-terminal propeptide (PINP) suggestive of 
increased bone turnover were found.5 ICTP levels correlated with markers of 
disease activity such as soluble IL-2 receptor (sIL-2R) and angiotensin 
converting enzyme (ACE). In addition, vertebral deformities suggestive of 
fractures were demonstrated in 20% of the subjects studied in this series. This 
may imply that the fracture risk in sarcoidosis is increased due to an increased 
bone turnover with consequent changes in microarchitecture and decrease of 
bone strength which is not reflected by changes in BMD.9,10 
If so, this may result in progressive vertebral deformities during the course of 
the disease. For this reason we re-examined individuals with sarcoidosis four 
years after the initial measurements to determine the incidence of new and/or 
progressive vertebral deformities and their relation with changes in BMD. 
Subjects and methods 
Subjects 
Sixty-six of the 124 subjects with sarcoidosis that were studied in 20025 agreed 
to participate in the follow-up study performed in 2006. None of the 58 subjects 
who declined or were unable to participate had impaired mobility or a history of 
vertebral fractures. The mean age of this group was 45 years and did not differ 
with respect to gender or glucocorticoid (GC) use from the group of subjects 
that were re-examined in 2006.  
Demographic, clinical and treatment data of the subjects studied in 2002 and 
2006 are summarized in Table 6.1.  
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Table 6.1 Baseline and follow-up demographic, clinical, and treatment variables (n=66). 
Variable Baseline 
(n=66) 
Follow-up 
(n=66) 
p* 
Demographic variables    
   Female sex 33 (50%)   
   Postmenopausal 11 (17%) 14 (21%) ns 
   Age (years) 43 (20-66)   
   Body mass index (kg/m2) 26.9 ± 5.7 27.2 ± 5.3 ns 
   Smoking 7 (11%)   
   Daily dietary calcium intake (mg) 740 (110-2360) 758 (150-1340) ns 
Clinical variables    
   Disease duration (years) 3 (1-22) 7 (5-26)  
   Chest X-ray stage (0-I-II-III-IV) 24/11/12/16/3 27/5/12/15/7 ns 
   FEV1 (% of predicted) 87 ± 28 91 ± 26 ns 
   DLCO (% of predicted) 87 ± 16 92 ± 18 ns 
   Physical activity  8.6 ± 3.7 8.1 ± 3.7 ns 
Laboratory values (in serum)    
   Calcium (mmol/l) 2.4 ± 0.1 2.4 ± 0.08 ns 
   1,25(OH)2D3 (nmol/l) 0.14 ± 0.03   
   ACE (U/l) 22.5 ± 9.8 15.3 ± 7.9 0.001 
   sIL-2R (kU/l) 654 (188-4315)   
   Hs-CRP (mg/l) 3.2 (0.2-191) 2.0 (1-16) <0.05 
   Z-score ICTP 0.7 ± 1.4   
   Z-score PINP -0.1 ± 0.9   
Treatment variables    
   GC use never 31 (47) 26 (39) ns 
   GC use previous 14 (21) 25 (38) <0.01 
   GC use current 21 (32) 15 (23) ns 
   Lifetime GC dose (mg) 9240 (200-48750) 11187 (200-56700) <0.001 
   Daily dose (mg)  12.4 ± 6.2 10.5 ± 3.3 <0.05 
   Started on bisphosphonates after 
baseline measurement 
 6 (9)  
Clinical risk factors for osteoporosis    
   Fracture > 50 years 2 (2/24=8%) 5 (5/28=18%) ns 
   Low body weight (<60 kg) 8 (12) 7 (11) ns 
   Severe immobilization 0 0 ns 
   Low physical activity index ≤5 18 (27) 18 (27) ns 
   Mother with hip fracture 6 (9) 7 (11) ns 
Data are given as mean ± SD, median (range) or number (%); * = p value between baseline and 
follow-up measurement. Reference parameters: Calcium: 2.1-2.6 mmol/l; 1,25(OH)2D3 0.040-
0.200 nmol/l; ACE: 9-25 U/l; sIL-2R: 241-846 KU/l; hs-CRP: <10 mg/l. Abbreviations: GC, 
glucocorticoid; FEV1, forced expiratory volume in one second; DLCO, diffusion capacity for carbon 
monoxide; 1,25(OH)2D3, 1,25 dihydroxyvitamin D; ACE, angiotensin converting enzyme; sIL-2R, 
soluble interleukin-2 receptor; Hs-CRP, high-sensitivity C-reactive protein; ICTP, carboxy-terminal 
cross-linked telopeptide of type I collagen; PINP, procollagen type I amino-terminal propeptide. 
 
 
The group consisted of 22 pre-menopausal women, 11 post-menopausal 
women, and 33 men; median age of the total group (all Caucasian) was 43 
years (20-66 y). The clinical records of all patients were reviewed. In 2002 
patients were evaluated according to a standard protocol that included 
questionnaires, measurement of height and weight, lung function, 
Thesis Caroline Heijckmann v05.p86   86 18-10-2007   8:53:41
 Vertebral deformities in sarcoidosis⏐87 
measurement of BMD, a single energy densitometry of the spine, and 
laboratory evaluation.5 In 2006 the same protocol was repeated with exception 
of the lung function tests. Informed consent was obtained from all participants 
and the study was approved by the medical ethics committee of our institution.  
Pulmonary evaluation 
Lung function measurements, including forced expiratory volume in one second 
(FEV1) and forced vital capacity (FVC), were measured with a 
pneumotachograph. The diffusion capacity for carbon monoxide (DLCO) was 
measured using the single-breath method (both Masterlab, Jaeger, Würzburg, 
Germany). Values were expressed as a percentage of those predicted.11 
Chest radiographs were graded according to the radiographic staging of 
DeRemee (0 to III), adding stage IV, the end stage of lung fibrosis.12,13 All 
interpretations were made by a radiologist who was blinded to the patient’s 
history. 
Laboratory assays 
Serum 1,25-dihydroxyvitamin D concentration was determined by 
radioimmuno-assay using a commercially available kit (IDS Ltd, Boldon, 
England, interassay coefficient of variation (IE-CV) 18%, intra-assay CV (IA-
CV) 15%). High-sensitivity C-reactive protein (hs-CRP) was measured by 
particle-enhanced immunonephelometry on the BN Prospec (Dade Behring). 
The detection limit is 0.175 mg/l and the measuring range is 0.175-1100 mg/l. 
Soluble IL-2 receptor (sIL-2R) was determined on the IMMULITE automated 
analyzer, by means of a two–site chemiluminescent enzyme immunometric 
assay with a measuring range of 50-7500 kU/l (Diagnostic Product Corporation, 
Los Angeles, CA, cat no LKIP1). Serum angiotensin converting enzyme (ACE) 
was measured using a colorimetric method. The precision of the ACE assay 
was < 5.6% and the reference interval for ACE was 9-25 U/l. 
As a marker for bone formation, serum procollagen type I amino-terminal 
propeptide (PINP) was measured. As a marker for bone resorption, serum 
carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) was 
assessed. Both PINP (IE-CV 3.2%, IA-CV 2.5%, lowest detectable 
concentration 0.4 µg/l) and ICTP (IE-CV 3.5%, IA-CV 2.3%, lowest detectable 
concentration <0.1 µg/l) were measured using commercial RIA kits (Orion 
Diagnostica Oy, Espoo, Finland). To adjust for age and gender Z-scores for 
these bone markers were obtained using a Dutch reference group (300 
women, 150 men), checked for normal BMD of the lumbar spine and femur and 
normal 25-hydroxyvitamin-D levels.14 
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Bone Mineral Density and Vertebral Morphometry 
Bone mineral density (BMD) was measured by dual X-ray absorptiometry 
(DXA, Hologic QDR 4500). In 2002 only the BMD of the hip was measured. In 
2006 the BMD of both the hip and of the lumbar spine were determined. As 
reference group the NHANES III database (sex- and age-matched) was used. 
A standard protocol as described previously was used for measurement of 
BMD. To adjust for age and gender, Z-scores were used. To examine changes 
in Z-scores between baseline and follow-up measurements a ∆ Z-score was 
calculated reflecting the difference between the Z-score at follow-up and the Z-
score at baseline. 
Furthermore, after bone density measurement a lateral single energy 
densitometry of the thoracic and lumbar spine for vertebral fracture assessment 
(VFA) was performed (also called Morphometric X-ray absorptiometry 
(MXA)).15 The scans obtained were analyzed twice by one trained operator 
(intra-observer correlation: 0.85), using the quantitative method of Genant.16 
The observer was blinded to the T-score values and to the values of the first 
set of measurements. After visual examination six points were placed on each 
vertebral body from T4 to L4. From these points three vertebral heights were 
measured anterior (Ha), mid (Hm) and posterior (Hp); On the basis of the 
average score of these morphometric measurements ratios were calculated 
and a prevalent vertebral deformity was defined as a reduction of height of 20% 
or more (Ha/Hp; Hm/Hp and Hp/Hp below). Severity of deformities was 
assessed using the scoring system of Genant.16 A score of ‘0’ was assigned to 
normal, non-fractured vertebra; ‘1’ for a mild deformity (20-25% reduction in 
anterior, middle or posterior vertebral height); ‘2’ for a moderate deformity 
(25-40% reduction) and ‘3’ for a severe deformity (>40% reduction). A new 
vertebral deformity was scored if a normal vertebra (grade 0) became 
deformed (grade ≥1) and a progressive deformity if the grade increased.16 
Questionnaires   
Calcium intake of all patients was scored in 2002 as well as 2006 on the basis 
of a detailed dietary list. Known clinical risk factors for osteoporosis (weight 
below 60 kg, mother with hip fracture, history of fractures after age 50, 
menopausal status and severe immobilization) as well as daily activities and 
exercise were assessed by a validated questionnaire,17 in which sports, daily 
and work activities are scored with a minimum of zero and a maximum of 
eighteen. GC therapy was evaluated by means of a patient questionnaire and 
verified using all the records of the patient’s pharmacist. It was scored as 
never, previous or current use and if subjects were currently using GCs, the 
daily dose was noted. 
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Statistics 
Student t-tests, chi-square tests, and one-way ANOVAs were used, depending 
on the variables and subgroups tested. Depending on the analysis, change 
scores or actual scores were used. Patients with new and/or progressive 
vertebral deformity were clustered for the multivariate and the receiver-
operating characteristics (ROC) analysis. Multivariate logistic regression 
analyses was performed to assess the strength of association between the 
incidence of new and/or progressive vertebral deformities and gender, age, 
weight, clinical risk factors, GC use, lifetime GC dose, daily GC dose, disease 
activity, bone markers, calcium intake, physical activity and BMD 
measurements. The variables that were entered in the multivariable analysis 
were those variables that appeared related (p<0.10) to this outcome measure 
in univariate analyses. Odds ratio (OR) and its 95% confidence intervals (CI) 
were calculated by using SPSS version 12.0. ROC analysis was used to 
assess the ability of various levels of the T-score femoral neck to predict the 
incidence of a new and/or progressive vertebral deformity. The ROC curve 
indicates the probability of a true-positive result as a function of the probability 
of a false-positive result for all possible threshold values.18 A p value <0.05 was 
considered statistically significant. 
Results 
Bone mineral density and bone turnover parameters 
The results of BMD measurements are shown in Table 6.2. The BMD of the 
total group remained unchanged after a median follow-up of 45 months (range 
35-49 months). When stratifying patients according to GC use, also no 
decrease in each of the subgroups was found. Patients that never used GCs 
showed a ∆ Z-score of the femoral neck (FN) of 0.03±0.36 and a ∆ Z-score of 
the trochanter of -0.08±0.37. In patients with previous use of GCs these ∆ 
Z-scores were 0.10±0.36 and 0.22±0.43 respectively. Even the group currently 
on GCs revealed no decrease of Z-score (∆ Z-score FN: 0.06±0.30 and ∆ 
Z-score trochanter: 0.00±0.18) and also the subgroup of postmenopausal 
women (n=11) did not show significant bone loss (∆ Z-score FN: 0.06±0.45 and 
∆ Z-score trochanter: -0.05±0.52). In the total group, bone turnover parameters 
at baseline showed an increased Z-score of ICTP compared to norm scores 
(0.7, 95% confidence interval (CI):0.4-1.1; p<0.001); on the other hand, the 
marker of bone formation (Z-score PINP) did not differ from the reference 
population. 
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Table 6.2 BMD variables at baseline and follow-up for the total group (n=66, median follow-up 
duration 45 months (range 35-49 months). 
Variable Baseline measurement Follow-up measurement p* 
BMD (gm/cm2)    
   Femoral neck 0.84 ± 0.12 0.83 ± 0.12 ns 
   Trochanter 0.74 ± 0.13 0.74 ± 0.12 ns 
   Total hip 0.97 ± 0.13 0.98 ± 0.14 ns 
   Lumbar spine  1.04 ± 0.14  
Z-score    
   Femoral neck 0.17 ± 1.0 0.23 ± 1.1 ns 
   Trochanter 0.27 ± 1.1 0.32 ± 1.1 ns 
   Total hip 0.18 ± 1.0 0.32 ± 1.0 0.001 
   Lumbar spine  0.03 ± 1.4  
T-score    
   Femoral neck -0.42 ± 1.0 -0.46 ± 1.0 ns 
   Trochanter -0.02 ± 1.1 -0.03 ± 1.0 ns 
   Total hip -0.14 ± 1.0 -0.10 ± 1.0 ns 
   Lumbar spine  -0.50 ± 1.3  
Data are given as mean ± SD; Abbreviations: BMD=bone mineral density; * p value between 
baseline and follow-up measurement. 
Clinical fractures and vertebral deformities 
Three new non-vertebral fractures occurred during the follow-up period. These 
included a hip fracture (twice in the same patient), an ankle fracture and a 
fracture of the thumb. All these fractures were related to trauma and occurred 
in subjects older than 50 years.  
Morphometric data are summarized in Table 6.3. In 2002 vertebral deformities 
(ratio of <0.80) were found in 19 vertebrae of 13 subjects. Seventeen of these 
were wedge and 2 biconcave deformities. No crush deformities were seen. The 
majority of these deformities was found in the low thoracic region. At follow-up 
a new vertebral deformity was scored if a normal vertebra (grade 0) became 
deformed (grade ≥1) and a progressive deformity if the grade increased.16 With 
this method, 36 vertebral deformities were found in 21 subjects. In one subject 
a vertebral deformity (ratio 0.78 of T11) found in 2002 was not found at follow-
up (ratio 0.81). So, in total 9 new subjects revealed one or more vertebral 
deformities, which means an increase of vertebral deformities from 20 to 32% 
of the subjects studied (p<0.05). From the 21 subjects with a vertebral 
deformity in 2006, 17 subjects (26% of total group) were diagnosed with one or 
more new or progressive vertebral deformities and in four subjects the 
deformity was unchanged compared to baseline. Data on number and severity 
of the deformities can be found in Table 6.3. Six patients were started on a 
bisphosphonate after baseline measurement and from these 6 patients, two 
had a new or progressive vertebral deformity at follow-up. 
Comparing the groups with and without new or progressive vertebral 
deformities at follow-up, no differences in ∆ Z-scores of BMD of the trochanter 
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or femoral neck (FN) were found (∆ Z-score trochanter -0.02±0.41 and 
0.08±0.38 respectively and ∆ Z-score FN 0.01±0.32 and 0.08±0.35). In addition 
no differences in baseline Z-scores of ICTP and PINP were seen between 
these groups. Multivariable logistic regression analysis, including factors that 
correlated in the univariate analysis, revealed that a T-score of the femoral 
neck at baseline (OR per 1 SD T-score reduction =2.5 (CI: 1.0-5.9), p=0.04), 
and a mother with a hip fracture (OR=14.1 (CI:1.4-142,6), p=0.02) were 
determinants of a new and/or progressive morphometric vertebral deformity at 
follow-up measurement. Factors such as age, gender, calcium in take, GC use, 
daily GC dose, lifetime GC dose, disease activity, bone markers, radiographic 
stage and disease duration at baseline did not predict new and/or progressive 
vertebral deformities. 
The threshold level of the T-score FN that maximized the combined specificity 
and sensitivity on the ROC curve (Figure 6.1) was <-0.45 for predicting a new 
and/or progressive deformity (sensitivity 88%, specificity 51%). 
 
Table 6.3 Number and grade of deformities. 
 Baseline Follow-up 
No. of subjects with deformity 13 (20%) 21 (32%)* 
No. of deformities   
   mild 17 28 
   moderate 2 8 
   severe 0 0 
Total 19 36 
* P <0.05 between number of subjects with deformity at baseline and follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 ROC curve using Femoral Neck T-score to identify patients with new and/or 
progressive vertebral deformity. Area under the curve (AUC): 0.72. Arrow: The 
threshold level of T-score FN that maximized combined specificity and sensitivity was 
<-0.45 (sensitivity 88 %, specificity 51%) 
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Discussion  
In this cohort of subjects with sarcoidosis a high prevalence of morphometric 
vertebral deformities suggestive of fracture was found, as well as a substantial 
increase in vertebral deformities during a follow-up period of four years. In 2002 
20% of subjects were diagnosed with vertebral deformities according to the 
criteria of Genant,16 which increased to 32% of all subjects in 2006. In parallel, 
the total number of deformities in these subjects almost doubled. However, 
BMD of the trochanter and femoral neck did not change over time and BMD of 
the lumbar spine at follow-up measurement did not differ from the reference 
population. These data are suggestive of an increased risk of progressive 
vertebral deformities in individuals with sarcoidosis despite preservation of 
BMD. 
Although data on prevalent or incident fractures in younger healthy populations 
are lacking, data from other studies suggest that the incidence and prevalence 
of vertebral deformities in this population are indeed high. Prevalence rates of 
30% asymptomatic vertebral fractures are demonstrated in elderly post-
menopausal women on chronic GC therapy using the same techniques.19 In a 
previous study in 60 subjects (mean age 49±13 years) with differentiated 
thyroid carcinoma we found vertebral deformities in 7% of patients.20 Data from 
the European Vertebral Osteoporosis Study (EVOS), a very large cross-
sectional population based study on European subjects aged 50 to 79 years, 
showed a prevalence of vertebral deformities of 12% (range 6-21%) in males 
and females.21 In the Rotterdam study, in which 3469 men and women aged 55 
years and older were studied, the prevalence of vertebral deformities 
suggestive of fracture was 6.9% in men and 7.5% in women.22 The 
epidemiology of vertebral fractures in women aged 50-54 years turned out to 
vary in different countries from 4.7%-11.5%.23 All these studies indicate that the 
fracture risk in subjects with sarcoidosis is substantial, regardless the 
differences in populations studied and differences in methodology. 
A new vertebral deformity was found in 15 subjects (23%). To identify incident 
deformities several approaches can be followed. Measurement of changes in 
vertebral heights of the same vertebral body from a baseline to a later 
radiograph in which a decrease in height of 15 or 20% or 4 mm is suggestive of 
fracture,24,25 changes in indices of vertebral area26 or changes in the number or 
presence of prevalent deformities.16,27 Black and co-workers evaluated these 
different approaches and concluded that none of these were consistently better 
than any other method.28 As we aimed to assess the change of numbers of 
subjects with one or more vertebral deformities over time we used the last 
method,16 in which changes in number of prevalent deformities are scored. A 
comparable approach was followed in the European Prospective Osteoporosis 
Study (EPOS)29 which revealed an incidence of new deformities of 3.4% after a 
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similar follow-up period. As the mean age of subjects included in this study was 
substantial higher than that of our cohort, these data cannot be used as a 
reference, although it is likely that in younger age groups even lower incident 
deformities would be observed. The high prevalence of vertebral deformities at 
baseline, the significant increase of more than 50% of subjects after follow-up 
with one or more deformity and the increase of severity of prevalent deformities 
all imply that sarcoidosis is a relevant risk factor for vertebral deformity.  
What is the underlying mechanism of this predisposition to vertebral deformities 
in view of the lack of effects on BMD in sarcoidosis? The load bearing capacity 
of bone, also referred as ‘whole bone strength’, depends on the amount of 
bone, the spatial distribution of the bone mass, and the intrinsic properties of 
the materials that comprise the bone. Thus, properties at the cellular, matrix, 
micro- and macroarchitectural levels may all impact the mechanical properties 
of bone.30,31 Apparently, in sarcoidosis mechanisms are involved that influence 
bone strength without having a significant impact on bone mass. As we found 
in the total group an increased marker of bone resorption (Z-score ICTP) at 
baseline, one of the possible mechanisms could be increased bone 
remodelling with a negative effect on bone microarchitecture that is not 
reflected by a change in BMD. It is well known that chronic inflammatory 
diseases influence bone physiology by the production of cytokines stimulating 
bone turnover.1,2,32 Increased bone remodelling is associated with an increased 
bone fragility and thus fracture risk33,34 and in postmenopausal women the level 
of bone turnover turned out to be an as strong and independent predictor of 
fractures as BMD.35,36 These data may support the hypothesis that the chronic 
inflammatory state in sarcoidosis results in increased bone remodelling with a 
negative effect on bone strength and thus an increased fracture risk. 
No changes in BMD in the group currently treated with GCs were found. This is 
unexpected as GCs are known to effect BMD via several mechanisms with 
consequent decrease of BMD. It may well be that this is due to intermittent GC 
use, as most of our patients were on intermittent glucocorticoids. Other studies 
have demonstrated that intermittent GC use has no major effects on BMD.37 A 
recent large retrospective cohort study on clinical fracture risk among patients 
from the UK General Practice Research Database showed that intermittent use 
of high dose of oral GCs was associated with only a small increase in the risk 
of osteoporotic fractures.38  
Despite the on average normal BMD, we found T-score of the femoral neck 
and a family history of hip fractures to be predictors of a new and/or 
progressive vertebral deformity. This suggests that the combination of a lower 
BMD in combination with the increased bone turnover in sarcoidosis 
predisposes to progressive vertebral deformity. If so, this would mean that in 
these high risk individuals preventive treatment should be considered to reduce 
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fracture risk. Controlled trials are needed, however, to substantiate this 
suggestion. 
Limitations of our study are the lack of an age- and sex-matched control 
population, and the lack of a “gold standard” for VFA. We followed the method 
of Genant,16 which is based on a reduction of the ratios of anterior, middle or 
posterior heights and all measurements were performed twice to improve 
accuracy. This is the simplest and most practical method39 and an association 
with future fracture risk is documented.40 The above mentioned EVOS study, 
however, applied the methodology described by McCloskey and Eastell and 
co-workers in which measurements are corrected for normal variations in 
vertebral shape.24 Relative to the method of Genant, the method of Eastell24 or 
McCloskey27 may have resulted in lower prevalences of vertebral deformities. 
This does however not explain the differences in prevalence of vertebral 
deformities reported elsewhere and in this paper. The restrictions of the 
methodology are also the limited ability to provide a differential diagnosis for 
the detected deformities, a lower sensitivity for milder fractures and the inability 
to evaluate the uppermost thoracic levels. Other disorders that may cause 
changes in vertebral shape involve congenital abnormalities and conditions as 
severe osteoarthritis41 and Scheuermann’s disease. We have, however, no 
indications that these relatively rare conditions may have interfered with our 
observations.  
In conclusion, we have shown that in subjects with sarcoidosis the number of 
vertebral deformities increases during the course of this disease, despite 
preservation of BMD. It appears that subjects with sarcoidosis have an 
increased fracture risk, even if BMD is normal. High risk individuals can be 
identified by a low-normal BMD and by a family history of hip fractures. 
Probably these individuals will benefit from therapies that increase bone 
strength. A T-score FN below -0.45 may be used to identify these individuals 
with a high sensitivity and an acceptable specificity. Studies evaluating the 
effects of such therapies in individuals with sarcoidosis are however clearly 
needed. 
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Abstract 
Background 
Previous studies from our group have shown that a high prevalence of vertebral deformities 
suggestive of fracture can be found in patients with an inflammatory disease, despite a near normal 
bone mineral density (BMD). As quantitative ultrasound (QUS) of the heel can be used for refined 
assessment of bone strength, we evaluated whether QUS can be used to trace subjects with an 
inflammatory disease at risk for fracture. 
 
Methods 
246 patients (mean age: 44±12.4 years) with an inflammatory disease were studied. QUS of the 
heel and BMD of the hip (by dual X-ray absorptiometry (DXA)) were measured. Furthermore lateral 
single energy densitometry of the spine for assessment of vertebral deformities was done. Logistic 
regression analysis was performed to assess the strength of association between the prevalence of 
a vertebral deformity and BMD and QUS parameters, adjusted for gender and age. 
 
Results 
Vertebral deformities (ratio of <0.80) were found in 72 vertebrae of 54 subjects (22%). In contrast to 
the QUS parameters BUA (broadband ultrasound attenuation) and SOS (speed of sound), T-score 
of QUS and T-scores of the femoral neck and trochanter (DXA) were lower in the group of patients 
with vertebral deformities. Logistic regression analysis showed that the vertebral deformity risk 
increases by about 60 to 90% per 1 SD reduction of BMD determined with DXA but not with QUS.  
 
Conclusions 
We have shown that QUS measurements of the calcaneus in patients with an inflammatory 
condition are not of value to identify patients at risk for fracture. 
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Introduction 
Osteoporosis is a skeletal disease characterized by low bone mass and 
microarchitectural deterioration resulting in increased bone fragility and hence 
susceptibility to fracture.1,2 The benchmark for the diagnosis of osteoporosis is 
the assessment of bone mineral density (BMD) with dual energy X-ray 
absorptiometry (DXA),2 as it is well established that the risk of future fracture 
rises with the decline of BMD. However, low BMD alone is not the only 
determinant of fracture risk3 and it is evident that assessment of fracture risk 
should encompass all aspects of risk and not be guided exclusively by results 
of bone mineral density measurements.4 In addition, in several conditions BMD 
evaluation provides a modest prediction of fracture risk. For example, the use 
of glucocorticoids (GCs) is a substantial risk factor for future fractures, which is 
largely independent of BMD.5,6 
We reported recently that a high prevalence of vertebral deformities suggestive 
of fracture can be found in patients who are considered at risk for secondary 
osteoporosis due to an inflammatory disease, such as sarcoidosis and 
inflammatory bowel disease (IBD), despite a near normal BMD.7 This may 
imply that bone strength is decreased in patients with inflammatory diseases, 
and that changes in bone microarchitecture rather than low BMD result in an 
increased fracture risk.8,9 
The last years there has been increasing interest in Quantitative Ultrasound 
(QUS) methods for refined assessment of bone strength.10 This noninvasive 
technique may assess microarchitecture and elasticity in addition to bone 
mineral density.11 Several studies have demonstrated that QUS of the heel can 
predict fracture comparable to and independent of spine and femur BMD, and 
that it can be used to identify patients with higher risk.12-14 Compared with DXA, 
QUS is less expensive, portable, does not require specially trained personnel 
and does not employ ionizing radiation.  
To evaluate whether QUS can indeed be used to identify subjects at risk for 
fracture irrespective of changes in BMD, we performed QUS on our series of 
subjects with sarcoidosis and IBD7 and compared the results with results of 
vertebral fracture assessment and BMD measurements with DXA. 
Subjects and methods 
Patients 
This is a cross-sectional study on 246 patients (mean age: 44±12.4 years) of 
which 87 were diagnosed with sarcoidosis and 159 with inflammatory bowel 
disease. All patients were Caucasians and diagnosed with sarcoidosis 
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according to the WASOG guidelines,15 based on consistent clinical features 
and results of an analysis of bronchoalveolar lavage fluid16 or with CD (n=95) 
or UC (n=64) on clinical grounds using endoscopic and/or radiological 
evidence, and by histological investigation of mucosal biopsies and/or surgical 
specimens when available. For confirmation of the CD diagnosis the Lennard-
Jones criteria17 and for UC the Truelove and Witts criteria18 were applied. 
The clinical records of all patients were reviewed. Demographic, clinical and 
treatment data of these patients are summarized in Table 7.1. None of the 
patients was on bisphosphonates.  
 
Table 7.1 Demographic, treatment variables and clinical risk factors in the study patients. 
Variable Total group 
(n=246) 
Age (years) 44 ± 12.4 
Males/premenopausal women/postmenopausal women 109/103/34 (44/42/14) 
Body mass index (kg/m2 ) 25.5 ± 4.7 
Sarcoidosis/CD/UC 87/95/64 (35/39/26) 
Disease duration (years) 6 (1-36) 
GC use never/ever/current 74/124/48 (30/50/20) 
Daily dose GC current group 12.9 (2.5-39) 
Fracture > 50 years 2/83 (2) 
Vertebral deformity by DXA 54 (22) 
Low body weight (< 60 kg) 44 (18) 
Low physical activity index ≤ 5 53 (22) 
Mother with hip deformity 16 (7) 
Data are given as mean ± SD, median (range) or number (%). Abbreviations: CD, Crohn’s disease; 
UC, ulcerative colitis; GC, glucocorticoid; DXA, dual-energy X-ray absorptiometry. 
 
 
Patients were evaluated according to a standard protocol that included 
questionnaires related to known clinical risk factors for osteoporosis (weight 
below 60 kg, hip fracture in the mother, history of fractures after age 50, 
menopausal status and severe immobilization),19 calcium intake, physical 
activity,20 measurement of height and weight and measurement of BMD. 
Glucocorticoid therapy was evaluated by means of a patient questionnaire and 
verified using all the records of the patient’s pharmacist. Informed consent was 
obtained from all participants and this study was approved by the ethical 
committee of the hospital. 
Bone mineral density and morphometry 
QUS and DXA measurements were performed. QUS was performed in the left 
calcaneus using a Sahara device (Hologic, Waltham, MA, USA). This 
equipment measures the broadband ultrasound attenuation (BUA) (dB/MHz) 
and the speed of sound (SOS) (m/sec) in a fixed region of interest in the central 
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calcaneal zone. The device combines the values of BUA and SOS to yield a 
parameter known as the “quantitative ultrasound index” (QUI) or stiffness, 
based on the following equation: QUI=0.41 * (BUA+SOS) -571. The QUI is also 
expressed as a T-score (reference data were those provided by the 
manufacturer). The heel of each patient was measured three times with 
complete repositioning between measurements. The definitive result was the 
mean of these three measurements. The coefficient of variation (CV) of the 
QUI was 1.4%. The instrument was subjected to daily quality control using a 
phantom provided by the manufacturer.  
BMD of the hip was measured by dual energy X-ray absorptiometry (DXA, 
Hologic QDR 4500, NHANES-III reference group). The hip was measured in 
the standard projection, and results were reported for femoral neck, trochanter 
and total hip. Standard procedures supplied by the manufacturer for scanning 
and analysis were performed. Calibration with the manufacturer’s spine 
phantom and quality control analysis was performed daily. The CV for BMD 
measurements was 1.0%. Furthermore, after bone density measurement a 
lateral single energy densitometry of the thoracic and lumbar spine for vertebral 
fracture assessment (VFA) was performed (also called Morphometric X-ray 
absorptiometry (MXA)).21 The scans obtained were analyzed twice by one 
trained operator (BD) (intra-observer coefficient of variation: 0.85), using the 
quantitative method of Genant.22 The observer was blinded to the T-score 
values and to the values of the first set of measurements. After visual 
examination six points were placed on each vertebral body from T4 to L4. From 
these points three vertebral heights were measured anterior (Ha), mid (Hm) 
and posterior (Hp); On the basis of the average score of these morphometric 
measurements ratios were calculated and a prevalent vertebral deformity was 
defined as a reduction of height of 20% or more (Ha/Hp; Hm/Hp and Hp/Hp 
below).22 Severity of deformities was assessed according to the method of 
Genant.22 A score of ‘0’ was assigned to normal, non-fractured vertebra; ‘1’ for 
a mild deformity (20-25% reduction in anterior, middle or posterior vertebral 
height); ‘2’ for a moderate deformity (25-40% reduction) and ‘3’ for a severe 
deformity (>40% reduction). 
Statistical analysis 
Student t-tests, chi-square tests, and one-way ANOVAs were used, depending 
on the variables and subgroups tested. Multivariate logistic regression analyses 
was performed to assess the strength of association between the prevalence of 
a vertebral deformity and BMD and QUS parameters, adjusted for gender and 
age. A p value <0.05 was considered statistically significant. Analyses were 
performed with SPSS version 12.0. 
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Results 
As summarized in Table 7.1, our series consisted of 103 pre-menopausal 
women, 34 post-menopausal women, and 109 men. The mean age (± SD) of 
this group of patients was 44±12.4 years and this was similar in both 
sarcoidosis and IBD. With QUS, the broadband ultrasound attenuation (BUA) 
value was higher in men than in women (78±16 versus 73±15 dB/MHz, 
p<0.005). No differences between the sexes of the other QUS parameters 
were found. The T- or Z-scores of FN or trochanter determined with DXA were 
not different between the sexes as well.  
T-scores of femoral neck and/or trochanter determined with DXA were in the 
osteopenic (T-score <-1 and >-2.5) or osteoporotic (≤-2.5) range in respectively 
50% and 2% of the patients studied, in total in 52%. In contrast, QUS of the 
calcaneus revealed a T-score below –1 in 32% of the patients. Correlations 
between DXA and QUS T-scores were r=0.35 for the T-score of the 
quantitative ultrasound index (QUI) with the T-score of the femoral neck 
(p<0.001) (Figure 7.1) and r=0.36 for the T-score QUI with the T-score of the 
trochanter (p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 T-score Femoral neck (DXA) versus T-score QUI (QUS).  
 Abbreviations: DXA, dual energy X-ray absorption; QUI, quantitative ultrasound 
index; QUS, quantitative ultrasound; IBD, inflammatory bowel disease. 
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Clinical non-vertebral fractures had occurred in two postmenopausal women. 
Vertebral deformities with VFA (ratio of <0.80) were found in 72 vertebrae of 54 
subjects (22%) with a higher prevalence in men (32%) than in women (14%). 
Sixty-one of these were wedge and 9 biconcave deformities. Two crush 
deformities were seen. Multiple vertebral deformities were observed in 6% of 
the entire cohort and 7% had one or more moderate or severe deformities.  
In Table 7.2 data of BMD measurements with DXA and QUS in the group of 
patients with or without vertebral deformities are summarized. Relative to the 
patients without vertebral deformities, those with vertebral deformities were on 
average older, and this group comprised more men. T-scores but not Z-scores 
of the femoral neck and trochanter (DXA) were lower in the group of patients 
with vertebral deformities. The T-score of the calcaneus (QUS) was also lower 
in this group of patients. No differences for the other ultrasound parameters 
were found between the groups with or without vertebral deformities. 
Furthermore, no differences were found in clinical risk factors, for the different 
diseases, GC use, disease duration, BMI, physical activity, calcium intake, 
current use of calcium and/or vitamin D supplements, aminosalicylates, 
immunosuppressive medication, and budenoside.  
 
Table 7.2 Bone variables in patients with and without any vertebral deformity, measured 
morphometrically.  
 Without deformity 
(n=192) 
With any deformity 
(n=54) 
All p* 
DXA variables     
   Femoral neck (g/cm2) 0.80 ± 0.12 0.76 ± 0.10 0.79 ± 0.11 <0.01 
   T-score  -0.66 ± 0.9 -1.16 ± 0.8 -0.77 ± 0.9 <0.001 
   Z-score -0.13 ± 1.0 -0.43 ± 0.9 -0.20 ± 1.0 ns 
   Trochanter (g/cm2) 0.72 ± 0.13 0.69 ± 0.10 0.71 ± 0.13 ns 
   T-score -0.21 ± 1.0 -0.51 ± 0.8 -0.27 ± 1.0 <0.05 
   Z-score 0.05 ± 1.1 -0.16 ± 0.8 0.00 ± 1.0 ns 
QUS variables     
   BUA (dB/MHz) 76 ± 16 73 ± 14 75 ± 16 ns 
   SOS (m/s) 1545 ± 89 1531 ± 99 1542 ± 92 ns 
   QUI 103 ± 45 94 ± 16 101 ± 41 ns 
   T-score -0.34 ± 1.1 -0.65 ± 0.9 -0.41 ± 1.0 < 0.05 
Data are given as mean ± SD or number (%); * p between patients with and without vertebral 
deformity; Abbreviations: DXA, dual-energy X-ray absorption; QUS, quantitative ultrasound; BUA, 
broadband ultrasound attenuation; SOS, speed of sound; QUI, quantitative ultrasound index.  
 
Table 7.3 gives odds ratios (OR) per 1 SD T-score reduction for any vertebral 
deformity for the three separate regression analyses. The vertebral deformity 
risk increases by about 60 to 90% per 1 SD reduction determined with DXA but 
not with QUS. 
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Table 7.3 Odds ratios for any vertebral deformity per 1 SD T-score reduction of various bone 
measurements adjusted for gender and age in patients with an inflammatory disease.  
 OR 95 % CI p 
BMD femoral neck 1.88 1.26-2.81 0.002 
BMD trochanter 1.63 1.12-2.37 0.01 
QUI 1.31 0.95-1.81 ns 
Abbreviations: OR, odds ratio; BMD, bone mineral density; CI, confidence interval; QUI, 
quantitative ultrasound index.  
Discussion  
Our study shows that in a group of patients with an inflammatory disease as 
sarcoidosis and  inflammatory bowel disease (IBD) none of the QUS variables 
had added value to recognize patients with a prevalent vertebral deformity 
suggestive of fracture.  
In several other studies QUS has been compared with DXA in patients with 
IBD. Robinson and co-workers23 studied 100 patients with Crohn’s disease 
(CD) and 52 age-matched controls and found lower values of both BUA and 
SOS in CD. The correlation between BUA and BMD-values determined at the 
hip and spine with DXA was, however, insufficient to recommend QUS as a 
screening tool. In another study, 53 patients with CD and 57 with ulcerative 
colitis (UC) were included and QUS variables (BUA and SOS) were compared 
with DXA-measurements of the hip and lumbar spine.24 Although this study 
also revealed a correlation between the QUS variables and DXA (r=0.50 to 
0.67), the agreement between measurements in individual patients was poor. 
Similar observations were made in two other studies on patients either with CD 
or UC.25,26 No studies with QUS have been performed in patients with 
sarcoidosis. 
A shortcoming of all the reported studies on the value of QUS in IBD is of 
course that they used BMD determined by DXA as gold standard, assuming 
that fracture risk increases with a decrease in BMD as in subjects without 
inflammatory conditions. No assessment of clinical and prevalent vertebral 
fractures was done. In our series, vertebral deformities suggestive of non-
clinical fractures were found in 22% of patients. The T-scores of these patients 
determined by both DXA and QUS were on average lower than those in 
patients without vertebral deformities. Although there was a correlation 
between T-scores determined with QUS and DXA, this correlation was 
moderate, as found by others.27 In addition, the calculated Odds ratios for any 
vertebral deformity per 1 SD T-score reduction was increased for BMD of the 
hip (DXA) but not for the QUI of the calcaneus. This supports the view that the 
predictive value of QUS in patients with inflammatory conditions is poor. 
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Our findings are in contrast with several large prospective studies that have 
shown that QUS of the calcaneus can predict fracture risk nearly as good as 
DXA.12-14 These studies are, however, all studies in elderly women and involve 
prediction of clinical (mainly non-vertebral) fractures. Kanis explored the 
relationship between QUS-determinations at the phalanges with age and the 
probability of symptomatic vertebral fractures and concluded that the 10-year 
probability of clinical vertebral fractures above the age of 45 increased for each 
SD decrease in measurement of SOS and fast wave amplitude (RR 1.7, 
respectively 2.4/SD).28 Studies on morphometric vertebral deformities and QUS 
parameters are, however, scarce. In 764 postmenopausal women (mean age 
73±6.4 years) the prevalence of nontraumatic vertebral fractures assessed with 
DXA was compared with an age matched control group with normal 
morphometry and this study showed that heel QUS enabled discrimination of 
women with fracture from those without.29 The same findings were reported in 
another study in postmenopausal women with rheumatoid arthritis.30 On the 
other hand, other studies revealed no differences in patients with and without a 
prevalent vertebral deformity. In one cross-sectional study in 551 post-
menopausal women (mean age 65.2±13.1) receiving chronic glucocorticoid 
therapy a high prevalence of asymptomatic morphometric vertebral fractures 
was found (37%), without any difference in QUS measurements between 
patients with and without deformities.31 This indicates that if QUS may be of 
any value to predict fracture risk, this will be in postmenopausal women and not 
in the type of patients included in our study. 
Although the T-scores of patients with vertebral deformities of our series were 
lower than in those without, the Z-cores, although available for DXA 
measurements only, were not different. This means that the differences in T-
score are likely due to differences in age rather than differences in disease 
activity. In addition, despite the fact that the T-scores were lower, they were 
certainly not diagnostic for osteoporosis, indicating that in inflammatory 
conditions, besides a decrease in BMD, changes in bone strength contribute to 
an increased risk for fracture.7  
In conclusion, in our hands QUS measurements of the calcaneus in patients 
with an inflammatory condition, such as sarcoidosis and IBD, were not 
associated with prevalent vertebral deformities and were not of value 
to recognise patients at risk for fracture. Hence, we feel that both BMD 
measurement with DXA and vertebral fracture assessment are better methods 
to identify such patients. Follow-up studies are, however, needed to 
substantiate this view. 
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General discussion 
The studies described in this thesis touch on the diagnosis of osteoporosis in 
subjects at risk and the clinical implications. The most important findings of the 
studies performed are: 
1. A substantial number of patients with an inflammatory condition as 
sarcoidosis and inflammatory bowel disease had vertebral deformities 
suggestive of fracture; 
2. Measurement of bone mineral density (BMD) appeared not of value to 
discriminate between patients with and without vertebral deformities; 
3. Bone turnover appeared increased in patients with an inflammatory 
disease. 
These findings indicate that patients with an inflammatory condition have an 
increased fracture risk due to increased bone remodelling and consequently a 
decreased bone strength independently of bone mass and BMD. 
In contrast, we found no increase of vertebral deformities in patients with 
differentiated thyroid carcinoma during treatment with a suppressive dose of 
levothyroxin. In these patients, BMD was also not different from sex- and age-
matched controls. These findings are in line with the publication of Reverter 
and co-workers who also found that the proportion of women with DTC with 
normal BMD, osteopenia, and osteoporosis is similar to that in healthy control 
women matched for body mass index and menopausal status.1 These 
observations imply that the effects of levothyroxine on bone metabolism and 
bone strength are minimal and not comparable to the effects of inflammation on 
bone. 
The questions that arise from these studies are how to define osteoporosis and 
how to involve vertebral fracture assessment (VFA) and bone turnover markers 
in this definition. In addition, to what extent other imaging techniques may 
contribute to a redefinition of osteoporosis and better recognition of patients at 
risk for fracture. 
In 1994, an expert panel convened by the World Health Organization (WHO) 
formulated an operational definition for osteoporosis for postmenopausal 
women on the basis of BMD with dual energy X-ray absorptiometry (DXA).2 
However, as the majority of fractures occur in persons without osteoporosis,3,4 
it is clear that bone density is not the only determinant for fracture. It is 
nowadays well recognized that relying on BMD alone as a predictor of fracture 
risk is of limited value, and that, in addition to fall and bone related risk factors, 
there is need to include other aspects of bone strength in the definition of 
osteoporosis as well. In support of this view, a later consensus conference has 
defined osteoporosis as ‘a skeletal disorder characterized by compromised 
bone strength leading to an increased risk of fracture’.5 Although BMD 
determined with DXA is strongly related to bone strength, it is only reflecting 
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part of its components.6 There is therefore a need for other imaging tools or 
markers to determine bone quality and hence to identify patients who are at 
risk for fragility fractures in a better way than can be done on the basis of DXA 
alone.  
One of the additional tools to recognize decreased bone strength appears to be 
VFA, as is illustrated by the studies summarized in this thesis. We found a high 
prevalence of vertebral deformities suggestive of fracture in the patients with 
inflammatory conditions irrespective of BMD. This indicates that these diseases 
have an effect on bone strength rather than bone mass and hence is illustrative 
for the relevance of VFA in addition to DXA to identify patients with reduced 
bone strength. 
As no data on non-clinical deformities in healthy young and premenopausal 
individuals are available yet, it is questionable whether the prevalence of 
vertebral deformities in inflammatory conditions we found is indeed high. The 
best comparison with healthy subjects is offered by the EVOS study, in which 
in a very large cross-sectional population based study, European subjects aged 
50 to 79 years were investigated. The prevalence of vertebral deformities on X-
rays in this study was 12% (range 6-21%) in males and females.7 In addition, 
the Rotterdam study, in which 3469 men and women aged 55 years and older 
were studied, revealed a prevalence of vertebral deformity suggestive of 
fracture in 6.9% of men and 7.5% of women.8 As the subjects described in our 
studies are younger and have hence a lower risk to fracture, the prevalence of 
vertebral deformities we found (21-25%) is probably indeed high. Furthermore, 
our unique prospective data in patients with sarcoidosis showed that the 
prevalence of vertebral deformities appeared increased from 20 to 32% after 
four years of follow-up, and in 26% of subjects one or more new or progressive 
vertebral deformities were diagnosed. This again supports the relevance of 
VFA to identify patients with an increased fracture risk and also the view that 
patients with a vertebral fracture have an increased risk for another vertebral 
fracture within a couple of years, irrespective of changes in BMD.9 
Unfortunately, one of the limitations of VFA is lack of a gold standard for 
vertebral fracture. This is the reason that we prefer the description ‘vertebral 
deformity suggestive of fracture’ rather than vertebral fracture as a natural 
interpretation of a vertebral deformity. Because of the absence of a gold 
standard, it is still not clear which method is the most appropriate to establish 
vertebral deformities and on the basis of that to determine the occurrence of 
vertebral fractures. For the determination of vertebral deformities a variety of 
morphometric approaches can be used. These different approaches can result 
in slightly different outcomes.10-13 Compared with subjective qualitative 
assessment, quantitative morphometry is a more reproducible method for 
assessing vertebral deformities and therefore these approaches are often used 
in conjunction. We followed the method of Genant,11 which is based on a 
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reduction of the ratios of anterior, middle or posterior heights and all 
measurements were performed twice to improve accuracy. This is the simplest 
and most practical method14 and an association with future fracture risk is 
documented.9,10,15 The above mentioned EVOS study, however, applied the 
methodologies described by McCloskey and Eastell and co-workers in which 
measurements are corrected for normal variations in vertebral shape.13 
Vertebrae in the mid-thoracic spine and thoraco-lumbar junction are slightly 
more wedged than in other regions of the spine12,16 and, as a result, with the 
method of Genant normal variations may be misinterpreted as mild vertebral 
deformities.17,18 This may have contributed to overestimation of vertebral 
deformities in our series, although we feel only to a limited extent. In one of our 
series (IBD patients), we also used the method of Eastell and this resulted in 
vertebral deformities in 20% of patients (data not shown), compared to 25% 
found with the method of Genant. This is indeed lower, but still indicates a 
substantial prevalence in this young population. 
We used X-ray absorptiometry (MXA) instead of standard radiographs (MRX) 
for morphometric determination of vertebral deformities. Several studies have 
documented that morphometric MXA is comparable to MRX (morphometric 
radiography) for this approach.19-22 Vertebral morphometry after MXA has 
several advantages over conventional radiographs. The radiation dose is much 
lower (<80µSv) and assessment of BMD and vertebral deformities can be 
combined. Although MXA is thus an established technology to detect vertebral 
deformities and to identify patients likely to benefit from pharmacological 
therapy who otherwise might not be treated,23 this technology has some 
limitations as well. These include limited ability to provide a differential 
diagnosis for the detected deformities, lower sensitivity for milder deformities 
and inability to evaluate the uppermost thoracic levels. However, its negative 
predictive value is high.24 Other disorders that may cause changes in vertebral 
shape involve congenital abnormalities and conditions as severe 
osteoarthritis25 and Scheuermann’s disease. These conditions usually present 
in a characteristic way and are relatively rare. We consider this disadvantage 
therefore not that relevant.   
One of the other alternatives to DXA to analyse bone mass and bone strength 
is quantitative ultrasound (QUS). QUS of the heel is shown to predict fractures 
comparable to DXA and independent of spine and femur BMD. As QUS is 
simple and easy to perform, some consider it a valuable tool to identify 
postmenopausal women with an increased fracture risk.26-28 The results of QUS 
are, however, rather variable, in particular in other populations than 
postmenopausal women. In our hands, QUS measurements in patients with an 
inflammatory disease were not associated with prevalent vertebral 
deformities and therefore likely not of value to recognize patients at risk for 
fracture. Similar observations have been made by other investigators.29,30 
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Hence, the value of QUS in the diagnostic work up of subjects at risk for 
osteoporotic fractures is still questionable. 
One more alternative to DXA is offered by three dimensional quantification of 
trabecular structure with high-resolution peripheral quantitative computed 
tomography (hr-pQCT) or micro-magnetic resonance imaging (µMRI). Although 
MRI is widely available, the measurement of bone microarchitecture requires 
special equipment and software. The method is still in development and 
therefore not applicable in daily practice yet.  
With hr-pQCT significant age-related changes in density, trabecular structure, 
and cortical thickness can be detected.31 In the OFELY cohort, a study on 
postmenopausal women, it is found that alterations of cortical and trabecular 
structure are associated with fragility fractures and that this association is 
partially independent of BMD assessed by DXA.32 Thus, hr-pQCT 
measurements appear useful for gaining an insight into structural mechanisms 
underlying various causes of skeletal fragility. At present, however, the majority 
of studies with hr-QCT are done in vitro on bone biopsies, or in vivo on the 
distal radius.32 The majority of hr-CT apparatus is still not adequate to study 
other sites in vivo, in particular the spine. As soon as these technical difficulties 
are overcome and apparatus become available to study the microarchitecture 
of vertebrae in detail, it can be expected that hr-QCT will replace DXA to study 
bone mass and bone strength resulting in better prediction of subjects with an 
increased fracture risk. 
In our studies we have clearly shown that both in patients with inflammatory 
bowel disease and in patients with sarcoidosis, increased bone turnover is 
associated with an increased fracture risk, even in patients with a normal BMD, 
which implies an effect of bone remodelling in these conditions on bone 
strength rather than bone mass.33 Long-term prospective studies have shown 
that markers of bone resorption in particular are beneficial in fracture 
prediction.34,35 In a study in elderly women the BMD-corrected risk of hip 
fracture increased by 1.4 (95% CI: 1.1-1.7) for each SD increase in urinary free 
deoxypiridinoline (D-Pyr) and by 1.3 (1.0-1.6) for urinary type 1 C-telopeptide 
(CTX). Garnero et al.36 found that a combination of high CTX and low BMD had 
an odds ratio of 4.8 for hip fracture in elderly women after a follow-up of on 
average 22 months. The same combination in women aged 65 years showed a 
relative risk of 4.2 for all fractures.37 These investigators demonstrated in 
another study, although without data of DXA, that the combination of history of 
fractures and urinary CTX may predict hip fracture risk in elderly women 
comparable to hip BMD determinations.38 Ross and co-workers found an 
association between spine and non-spine fractures and high serum bone 
alkaline phosphatase, with an odds ratio of 1.5-1.9 per 1 SD change, which 
persisted after adjustment for BMD.39 These studies indicate that indices of 
skeletal turnover give information on fracture risk independently of BMD and 
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might therefore complement and improve fracture risk assessment by BMD. 
These studies are, however, all performed in postmenopausal women only. 
Prospective studies with fracture endpoints in men and in patients at risk for 
secondary osteoporosis, like the patient groups we have studied, are lacking. 
Beside this, the question arises whether measuring bone turnover may be 
helpful in estimating fracture risk in patients with T-scores above -2.5, and 
whether medical intervention in subjects with osteopenia but elevated bone 
markers may lead to a reduction in fractures. A recent study demonstrated that 
with measurement of bone turnover markers a subset of post-menopausal 
women can indeed be identified in which therapy with bisphosphonates is cost-
effective.40 Further studies are however needed to substantiate this finding. 
Are patients with inflammatory conditions in whom vertebral deformities have 
been demonstrated, candidates for preventive treatment with - for instance - 
antiresorptive medications like bisphosphonates? According to current 
guidelines, patients with prevalent vertebral fractures or a BMD T-score less 
than -2.5 should receive treatment. Many guidelines are available on the 
prevention and treatment of patients that are expected to be, or already are, on 
long-term (>3 months) glucocorticoid treatment. Treatment with oral 
glucocorticoids has been associated with increase in the risk of fractures, 
particularly fractures of the hip and vertebrae and this may be partially 
independent of BMD.41 This effect is dose dependent and occurs rapidly after 
the start of treatment.42 However, intermittent use of high-dose oral 
glucocorticoids (daily dose ≥15 mg and cumulative exposure ≤1 gm) may result 
in only a small increased risk of osteoporotic fractures. Conversely, patients 
who receive several courses of high-dose oral GCs (daily dose ≥15 mg and 
cumulative exposure ≥1 gm) have a substantially increased risk of fractures.43 
In the Dutch guidelines, bone measurement is not considered necessary in 
high risk patients, e.g. those who will take >60 mg/day of hydrocortisone or 
another equipotent glucocorticoid for more than three months. In such patients 
preventive treatment is indicated, irrespective of BMD values. The same is 
recommended for postmenopausal women and older men (>70 years) who will 
take intermediate doses (30-60 mg hydrocortisone). In all other patients on 
glucocorticoids a DXA measurement is recommended and if it is found to be 
low (a T-score of <-2.5), treatment should be started.44-46 In patients not on 
glucocorticoids, a BMD measurement is recommended for a) those with a 
clinical fracture above 50 years, b) patients older than 60 years and at least 
three clinical risk factors and c) patients >70 years with two risk factors.44 
Specific guidelines for patients with IBD or sarcoidosis do not exist. As both we 
and others found a high prevalence of vertebral deformities in IBD patients, 
whereas no discrimination between patients with and without a vertebral 
deformity could be made with DXA, we feel that in this type of patients 
morphometric assessment of vertebral deformities better reflects reduced bone 
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strength than DXA measurements. As we found in patients with sarcoidosis not 
only a relevant prevalence of vertebral deformities during the initial cross-
sectional study, but also a substantial increase of incident deformities after four 
years of follow-up, one may even wonder whether in this type of patients 
preventive treatment should be instituted, irrespective of the results of BMD or 
VFA-studies.    
If preventive treatment in subjects at risk is considered, the next question is, 
which class of medication is to be preferred and for how long the therapy 
should be continued. At present, the drug of choice for prevention of 
osteoporotic fractures is a bisphosphonate. If this drug is not tolerated, 
strontium ranelate can be considered. Both types of drugs have been proven to 
be effective in the reduction of the risk of vertebral fractures (40-50%) and non-
vertebral fractures (20-40%).47-49 If there is progress of fractures during 
treatment, recombinant human parathyroid hormone (rhPTH) 1-34 fragment of 
the whole rhPTH 1-84 can be considered. Unlike bisphosphonates, that act 
mainly by reduction of bone resorption, and strontium ranelate, that at least in 
animal models acts by both reduction of bone resorption and stimulation of 
bone formation, daily injections of rhPTH primarily stimulate bone formation, 
more than bone resorption.50 Phase III trials with rhPTH (1-34) in 
postmenopausal women demonstrated a 65% reduction in risk of new vertebral 
fractures and a 53% reduction of non-vertebral fractures,51 while for rhPTH (1-
84) only a reduction of vertebral fractures could be demonstrated.52 So, rhPTH 
appears to be at least as effective as bisphosphonates and strontium ranelate 
in the prevention of fractures, which may be relevant if treatment is considered 
in patients with a substantial fracture risk, as in patients with an inflammatory 
disease. However, because of still existing safety concerns, the high cost and 
the fact that treatment periods are at this moment limited to 18-24 months, the 
benefit in terms of bone mineral density seems to wane after discontinuation 
unless followed by an antiresorptive agent, we feel that also in patients with an 
inflammatory disease parathyroid hormone is a second line drug and that 
bisphosphonates or strontium ranelate are the first drugs of choice.  
As for the period that treatment should be continued in patients with an 
inflammatory disease, no data are available. So far, available data of oral 
bisphosphonate treatment in postmenopausal women for up to 10 years, show 
sustained, but not progressive, suppression of bone remodelling and provide 
no evidence of an adverse effect of bisphosphonates on bone metabolism. In 
addition, the favourable effect of bisphosphonates on skeletal integrity seems 
to be sustained.53 At present, the usual policy is to reconsider continuation of 
treatment after five years. It is our policy to continue treatment if after five years 
treatment the T-score with DXA is still <-2.5 and/or a vertebral fracture is 
evident or new risks appear. In low risk patients (T-score >-2.5, no new 
fracture) we are used to give a drug holiday. This may be different in patients 
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with an inflammatory disease as long as activity of the disease is still notable. 
Follow-up studies are, however, needed to clarify this point. 
Recommendations for further studies 
Although our studies point to a high prevalence of vertebral fractures in patients 
at risk for secondary osteoporosis and hence new fractures, these data would 
be strengthened by studies that evaluate the presence of vertebral deformities 
in healthy young populations. Prospective follow-up studies in patients with IBD 
will have to demonstrate whether a similarly high rate of new deformities as in 
patients with sarcoidosis can be found. Finally, intervention studies on patients 
with vertebral deformities, irrespective of BMD-measurements, are needed to 
determine whether or not recognition and treatment of such patients reduce the 
incidence and progression of vertebral deformities.  
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Summary 
In this thesis several aspects of bone quality in patients at risk for secondary 
osteoporosis are studied. In chapter 2 an overview of osteoporosis and fracture 
risk is given. The subsequent chapters involve studies on clinical risk factors 
and measurements of bone mineral density, bone turnover and prevalent 
vertebral fractures in patients with thyroid carcinoma, sarcoidosis or 
inflammatory bowel disease (IBD). 
 
In chapter 3 a study is described in which we investigated the influence of a 
suppressive dose of levothyroxin on bone in patients with differentiated thyroid 
carcinoma. Z-scores of bone mineral density (BMD) were not different from the 
reference population, even after long-term (>10 years) suppression therapy. 
Patients with a BMD in the lowest and highest quartile showed significant 
differences in the presence of known clinical risk factors. The bone turnover 
parameter carboxy-terminal cross-linked telopeptide of type I collagen (ICTP, a 
marker of bone resorption) was higher than in age-matched controls. In 
addition, we found in 7% of patients a vertebral deformity, suggestive of 
fracture. As data on vertebral fractures in healthy young patients are lacking, 
the best comparison we have is the EVOS study, comprising a very large 
cross-sectional population based study on the prevalence of vertebral 
deformities in European men and women. In this study, in a group of 15570 
males and females aged 50-79 years, a prevalent vertebral deformity was 
observed in 12% (range 6-21%). We therefore had no indication that the 
prevalence of vertebral fractures in this particular patient group is higher than in 
a European reference population. In all studies published thus far on this 
subject, a significant bone loss was observed in patients using a 30-50% higher 
dose of levothyroxin than in our study. We therefore concluded that patients 
with well-differentiated thyroid carcinoma are not at increased risk of 
developing low bone mass nor have a higher prevalence of vertebral fracture, 
at least when treated with levothyroxin with doses not higher than necessary to 
suppress TSH.  
 
Chapter 4 involves a study on the prevalence of vertebral deformities in IBD 
patients and their relation with BMD and bone turnover. Vertebral deformities 
were found in 25% of patients either with Crohn’s disease (CD) or ulcerative 
colitis (UC). Comparing patients with and without vertebral deformities, no 
significant difference was found between Z- and T-scores of BMD, or levels of 
ICTP and serum procollagen type I amino-terminal propeptide (PINP). Neither 
disease activity, bone turnover markers, clinical risk factors, nor BMD were 
predictive for the presence of vertebral deformities. The determinants for 
having more than one vertebral deformity were age and glucocorticoid use. 
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This may imply that in addition to screening for low BMD, morphometric 
assessment of vertebral deformities is warranted in CD and UC to identify 
patients with decreased bone quality and consequently an increased fracture 
risk. 
 
Sarcoidosis is a chronic inflammatory T-cell-driven disease that can also affect 
bone. In chapter 5, a study is summarized regarding bone remodelling, BMD 
and prevalent vertebral deformities in patients with sarcoidosis and their 
dependency of disease-related and treatment-related factors. We found that 
hip BMD was normal in patients with sarcoidosis, despite an increased bone 
turnover. As the increased bone resorption was found to be related to 
angiotensin converting enzyme (ACE) and soluble IL-2 receptor (sIL-2R), we 
concluded that this is - at least partly - the result of disease activity. In addition, 
vertebral deformities suggestive of fracture were found in a significant number 
of patients (21%). This implies that in sarcoidosis increased bone turnover 
affects bone quality rather than bone density.  
 
As we found a high incidence of morphometric vertebral deformities suggestive 
of fractures in this patient group, the aim of the subsequent follow-up study was 
to determine the incidence of new and/or progressive vertebral deformities and 
the evolution of BMD during the course of sarcoidosis (chapter 6). The BMD of 
the total group appeared unchanged after follow-up, even in the groups with 
current or previous glucocorticoid use. The prevalence of vertebral deformities, 
however, appeared increased from 20 to 32% in the total group, and in 26% of 
subjects one or more new or progressive vertebral deformities were diagnosed. 
We found that the combination of a low normal BMD and a family history of 
fragility fractures confers an increased risk of the incidence of these 
deformities.  
 
The last years there has been increasing interest for Quantitative Ultrasound 
(QUS) methods for refined assessment of bone strength. We hypothesized that 
in these populations (IBD and sarcoidosis) with decreased bone strength as 
reflected by the presence of vertebral deformities but with preservation of BMD, 
QUS measurements might have additional value to BMD measured with DXA 
to predict the presence of morphometric vertebral fractures. This is the subject 
of chapter 7. In addition to measurement of QUS vertebral fracture assessment 
and BMD measurement with DXA was done to determine whether or not QUS 
could be used to identify subjects with an inflammatory disease at risk for 
fracture. It appeared that, in contrast to DXA, decrease of bone density 
parameters of calcaneal QUS measurements was not associated with 
prevalent vertebral deformities and is hence not a useful clinical tool to identify 
patients at risk for fracture.  
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The studies described in this thesis imply that in subjects with inflammatory 
diseases who are at risk for secondary osteoporosis both DXA BMD 
measurements and assessment of vertebral deformities are warranted to 
identify individuals with reduced bone strength. 
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Samenvatting 
In dit proefschrift wordt een aantal studies beschreven waarin verschillende 
aspecten van de kwaliteit van bot bij patiënten met een hoog risico op 
secundaire osteoporose zijn bestudeerd. In hoofdstuk 2 wordt een overzicht 
van osteoporose en het risico op botbreuken gegeven. De daarop volgende 
hoofdstukken gaan over klinische risicofactoren, metingen van de botdichtheid, 
botombouwparameters en de aanwezigheid van werveldeformiteiten bij 
patiënten met een schildkliercarcinoom, sarcoïdose of een inflammatoire 
darmziekte.  
 
In hoofdstuk 3 is een studie beschreven waarin we de invloed van een 
suppressiedosis van levothyroxine op bot hebben onderzocht bij patiënten met 
een schildkliercarcinoom. Wij vonden dat Z-scores van de met behulp van 
“dual-energie X-ray absorptiometry (DEXA)” gemeten botdichtheid niet 
verschillend waren van de referentiepopulatie, zelfs niet na langdurige (≥ 10 
jaar) suppressietherapie. Patiënten met een botdichtheid in het laagste en 
hoogste kwartiel toonden een significant verschil in de aanwezigheid van 
klinische risicofactoren. Daarnaast bleek de marker van botresorptie (ICTP) 
hoger te zijn dan bij gezonde controlepatiënten van dezelfde leeftijd en vonden 
we bij 7% van de patiënten een werveldeformiteit, suggestief voor een 
wervelfractuur. Hoewel gegevens over wervelfracturen bij gezonde jonge 
mensen ontbreken, zijn onze resultaten het beste te vergelijken met de 
gegevens van een grote Europese studie naar de aanwezigheid van 
werveldeformiteiten bij mannen en vrouwen (EVOS) in de leeftijd van 50-79 
jaar. In deze studie (15570 mannen en vrouwen) werd een werveldeformiteit 
gevonden bij 12% (range 6-21%). We hebben derhalve geen aanwijzingen dat 
werveldeformiteiten vaker voorkomen bij onze patiëntengroep dan bij deze 
Europese referentiepopulatie. In alle tot op heden over dit onderwerp 
gepubliceerde studies werd met name een significant botverlies gezien bij 
patiënten die een 30-50% hogere dosis levothyroxin kregen dan in onze studie. 
We hebben daarom geconcludeerd dat indien patiënten met een goed 
gedifferentieerd schildkliercarcinoom behandeld worden met levothyroxin 
doses niet hoger dan nodig om het TSH te supprimeren, ze geen verhoogd 
risico hebben op het ontwikkelen van een verlaagde botmassa of een 
wervelfractuur. 
 
In hoofdstuk 4 wordt een studie beschreven naar de aanwezigheid van 
werveldeformiteiten in een groep patiënten met een inflammatoire darmziekte 
en de relatie van deze deformiteiten met botdichtheid en botombouw-
parameters. Werveldeformiteiten werden gevonden bij 25% van zowel de 
patiënten met de ziekte van Crohn als met colitis ulcerosa. Er werd geen 
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verschil gevonden in Z- of T-scores van de botdichtheid of hoogte van de 
botombouwparameters tussen patiënten met en patiënten zonder een 
werveldeformiteit. Zowel ziekteactiviteit als botombouwparameters, klinische 
risicofactoren en botdichtheid bleken géén voorspellers voor de aanwezigheid 
van werveldeformiteiten. De determinanten voor het hebben van meer dan één 
werveldeformiteit waren leeftijd en gebruik van corticosteroïden. Dit kan 
betekenen dat in aanvulling op het screenen op een verlaagde botdichtheid, 
morfometrie van de wervels eveneens gerechtvaardigd is in deze groep, 
namelijk om die patiënten te identificeren die een verminderde kwaliteit van het 
bot hebben en als gevolg daarvan een toegenomen fractuurrisico. 
 
Sarcoïdose is een chronische inflammatoire ziekte die ook het bot kan 
aantasten. In hoofdstuk 5 is een studie beschreven over botombouw, 
botdichtheid en het aanwezig zijn van werveldeformiteiten bij patiënten met 
sarcoïdose en hun relatie met ziekte- en behandelingsgerelateerde factoren. 
We vonden dat de botdichtheid van de heup normaal was bij deze patiënten, 
ondanks een verhoogde botombouw. Omdat de parameter van botresorptie 
gerelateerd bleek aan “angiotensin converting enzyme (ACE)” en de “soluble 
IL-2 receptor (sIL2R)” concludeerden wij dat een verhoogde botresorptie het 
resultaat zou kunnen zijn van een verhoogde ziekteactiviteit. Daarnaast vonden 
we werveldeformiteiten, suggestief voor fracturen bij een groot aantal patiënten 
(21%). Dit impliceert dat bij sarcoïdose een toegenomen botombouw de 
botkwaliteit meer aantast dan de botdichtheid.  
 
Omdat we in deze patiëntengroep een hoge incidentie van morfometrische 
werveldeformiteiten vonden was het doel van de follow-up studie om vast te 
stellen wat het voorkomen zou kunnen zijn van nieuwe en progressieve 
werveldeformiteiten en hoe de botdichtheid zou veranderen gedurende het 
beloop van sarcoïdose (hoofdstuk 6). De botdichtheid van de totale groep 
bleek na follow-up onveranderd, zelfs in de groep met gebruik van 
corticosteroïden. Het aanwezig zijn van werveldeformiteiten bleek echter 
toegenomen van 20 naar 32% van de totale groep en bij 26% van de patiënten 
werden één of meer nieuwe of progressieve werveldeformiteiten 
gediagnosticeerd. Wij vonden dat een lage botdichtheid en een 
familieanamnese met heupfracturen een verhoogd risico gaf op deze 
deformiteiten. 
 
De laatste jaren is er een toegenomen interesse ontstaan voor ultrageluid als 
methode om een indruk te krijgen over de sterkte van bot. Onze hypothese 
was dat in de bestudeerde populaties waarbij we een afgenomen botsterkte 
vonden - zich uitend in aanwezigheid van werveldeformiteiten - maar toch een 
normale botdichtheid, een ultrageluidmeting van de hiel van additionele waarde 
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zou kunnen zijn naast een botdichtheidsmeting met DEXA. Dit om de 
aanwezigheid van morfometrische wervelfracturen te voorspellen (hoofdstuk 
7). Het bleek dat de ultrageluidparameters van de hiel niet geassocieerd waren 
met het aanwezig zijn van werveldeformiteiten. Geconcludeerd is dus dat 
meting van de botdichtheid met ultrageluid geen bruikbaar instrument is om 
patiënten met verhoogd risico op een fractuur te identificeren. 
 
De studies beschreven in dit proefschrift impliceren, dat bij patiënten met een 
inflammatoire ziekte die een verhoogd risico hebben op secundaire 
osteoporose, zowel een botdichtheidsmeting met DEXA als het bepalen van 
werveldeformiteiten nodig zijn om individuen met een verlaagde botsterkte, met 
als gevolg een toegenomen fractuurrisico te identificeren. 
Thesis Caroline Heijckmann v05.p133   133 18-10-2007   8:53:46
134⏐Chapter 10 
 
Thesis Caroline Heijckmann v05.p134   134 18-10-2007   8:53:46
  
 
 
 
 
8 
Dankwoord 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis Caroline Heijckmann v05.p135   135 18-10-2007   8:53:46
136⏐ 
Thesis Caroline Heijckmann v05.p136   136 18-10-2007   8:53:46
 Dankwoord⏐137 
Dankwoord 
In 2000 ben ik begonnen met de eerste voorbereidingen voor deze studies. Ik 
heb er lang aan getwijfeld of ik ooit de eindstreep zou halen. Nu, ruim 7 jaar 
later, worden alle inspanningen beloond met dit proefschrift. Zonder de hulp 
van vele mensen die mij de ruimte en de mogelijkheden gaven en mij 
motiveerden om door te gaan, was dit zeker niet gelukt.  
 
Dr. M.S.P. Huijberts, mijn begeleider en co-promotor, wil ik als eerste noemen. 
Lieve Maya, voor een (mental) coach als jij, met jouw eindeloze inzet en 
enorme werklust, schieten woorden tekort om je te bedanken. Niet alleen op 
wetenschappelijk gebied ben je belangrijk voor me geweest maar ook als 
vriendin. Naast een aantal leuke congressen, hebben we ook al vele mooie 
vakanties met onze gezinnen samen doorgebracht. Ongetwijfeld zal ik me, nu 
ik meer “vrije tijd” ga krijgen, verder gaan bekwamen op culinair gebied. Ik 
hoop dan ook je ooit nog eens als “chalet girl” te kunnen evenaren. Ik kijk uit 
naar nog vele mooie en gezellige momenten samen. 
 
Prof. dr. A.C. Nieuwenhuijzen Kruseman, beste Arie, met jouw hulp zijn er 
grote hindernissen genomen. Knopen werden vlot doorgehakt en geen enkel 
probleem leek onoverkomelijk. Het is bekend dat een promotieonderzoek 
zelden zonder tegenslagen verloopt, maar de hindernissen op mijn weg waren 
- voor mijn gevoel - soms wel buitenproportioneel. Jouw stimulerende woorden 
zijn op bepaalde momenten van cruciaal belang geweest. Ik wil je hartelijk 
danken voor de manier waarop je het hele proces hebt bewaakt en voor je 
bereidheid om samen met mij dit proefschrift tot een goed einde te brengen.  
 
Prof. dr. P. Geusens, beste Piet, jouw ongekende enthousiasme zorgde ervoor 
dat ik telkens blij terugkwam uit Maastricht. Jij gaf me steeds het gevoel met 
heel belangrijke dingen bezig te zijn. Ik ben je zeer erkentelijk voor alle 
opbouwende commentaren, ideeën en de telkens weer snelle en kritische 
beoordeling van alle manuscripten. 
 
Prof. dr. B.H.R. Wolffenbuttel, beste Bruce, ons eerste gesprek over dit 
onderzoek aan het keukentafeltje van ons appartement in Breda kan ik me nog 
als de dag van gisteren herinneren. De eerste gedachten hebben we toen op 
papier gezet. Tijdens deze fase en de praktische uitvoer van de studie heb je 
een heel belangrijke rol gespeeld. Ik ben je daar zeer dankbaar voor.  
 
Prof. dr. M. Drent, beste Marjolein, bedankt voor de heel prettige samen-
werking. Je hulp en enthousiasme tijdens de afgelopen jaren heb ik zeer op 
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prijs gesteld. Jouw passie voor het vak en je gedrevenheid zijn een voorbeeld 
voor me. 
 
Prof. dr. J. de Vries, beste Jolanda, dank voor je onmisbare hulp bij de 
statistische analyses. Ik heb veel van je geleerd. Telkens lukte het je snel tijd 
voor me vrij te maken om weer eens een vraag te beantwoorden.  
 
Dr. P.P.C.A. Menheere, beste Paul, dank voor al je inspanningen om het 
bepalen van de botmarkers te realiseren. Dr. E. van der Veer, beste Eveline, 
ook jou ben ik zeer dankbaar voor je positieve woorden en voor de 
mogelijkheid die je hebt gegeven om Z-scores van onze botombouw 
parameters te berekenen.  
 
Prof. dr. R.W. Stockbrügger, beste Reinhold, dank voor de plezierige 
samenwerking en het meedenken over de IBD-data. Dr. E.J. Schoon, beste 
Erik, jouw pionierswerk op het gebied van osteoporose bij IBD patiënten is ook 
weer van belang geweest voor dit onderzoek. Ik dank je voor de begeleiding en 
het becommentariëren van de stukken. 
 
Dr. J.R. Juttmann, beste Job, dankzij jou ben ik in het onderzoeksgebied van 
osteoporose terecht gekomen. Deze interesse is mede door jou ontstaan en 
heeft uiteindelijk geleid tot dit onderzoek. Daarnaast was je samen met dr. C. 
van der Heul verantwoordelijk voor mijn opleiding in Tilburg. Ik heb er veel 
geleerd, waarvoor ik jullie zeer dankbaar ben. Ik denk met veel plezier terug 
aan de “rode-bankjes-tijd” en wil daarvoor ook mijn collegae arts-assistenten 
bedanken. 
 
De leden van de beoordelingscommissie: prof. dr. G.J. Dinant, prof. dr. J.M.A. 
van Engelshoven, prof. dr. A.A.M. Masclee, prof. dr. G.J.J. Teule en prof dr. 
E.F.M. Wouters dank ik voor het kritisch doorlezen van het manuscript. 
 
Dany Simon heeft een heel belangrijke rol gespeeld bij het coördineren van de 
studie, het zien van de patiënten en het invoeren van de data. Ik dank ook 
Pauline Versteeg, Esther ten Hoor, Gé van Kan voor hun hulp hierbij. Petal 
Wijnen heeft gezorgd voor de database met de sarcoidose patienten. Lia van 
Iersel en haar collega’s dank ik voor het maken van de DEXA’s en hun 
bereidheid om alle onderzoeken tussendoor in te plannen.  
 
Uiteraard dank ik ook Tiny Wouters, die een belangrijke rol heeft gespeeld in 
de laatste fase van het proefschrift.  
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Dear Bianca, without your tremendous efforts it would not have been possible 
to do all the morphometric measurements. Even when you were in Bucharest it 
seemed like you were sitting next door. Debby Vosse dank ik voor het delen 
van de promotie-emoties, het samen werken aan onze data was iets minder 
succesvol. Ik hoop dat ook jouw proefschrift binnenkort afgerond kan worden. 
 
Maatschap interne geneeskunde ziekenhuis Bernhoven. Beste collegae: de 
gezelligheid en een goede dosis humor zorgen ervoor dat ik elke dag weer met 
veel plezier naar het ziekenhuis ga. Het is een voorrecht om met kundige 
collega’s in zo’n prettige sfeer te mogen werken en ik hoop dat er zo nog vele 
jaren zullen volgen. 
 
Lieve hulptroepen in huis: Kim, Celia, Šefika en Asim. Jullie vormen mede de 
veilige basis thuis voor onze kinderen en zorgen dat het huishouden altijd 
perfect draait. Zonder jullie hulp zou dit alles zeker niet gelukt zijn.  
 
Mijn paranimfen, lieve Corinne en Tamara. Goede en iets minder goede tijden 
hebben we met elkaar gedeeld. Ik dank jullie voor jullie vriendschap, 
gezelligheid en warmte. Ook veel dank aan Joop en Anneke, jullie hebben 
gezorgd voor veel momenten waaruit ik weer energie kon putten om door te 
gaan. En lieve An, de tocht door de Alpen is inderdaad gelopen, maar met het 
kabelbaantje de Mont Blanc op is toch ook nog vermoeiend. Ik probeer nu 
alleen wel van het uitzicht te genieten! Dank voor je bemoedigende woorden. 
Alle andere vrienden dank ik voor het begrip dat ik het toch te regelmatig heb 
laten afweten.  
 
Mijn lieve ouders. Jullie hebben ervoor gezorgd dat ik ben geworden wie ik nu 
ben. Mijn “drive” en doorzettingsvermogen dank ik aan jullie en die 
karaktereigenschappen hebben mij enorm geholpen in dit traject. Ik ben jullie 
ongelofelijk dankbaar voor alles wat jullie voor mij hebben gedaan en nog 
steeds doen. Ik realiseer me dat ik de laatste jaren wel eens te weinig tijd en 
aandacht voor jullie heb gehad maar ik hoop dat het voltooien van mijn 
proefschrift dat een beetje goed kan maken.  
 
Mijn broers, Frank en Martijn. De periode dat jullie last hadden van de ijverige, 
brave, grote zus die op school te goed haar best deed en alleen maar goede 
cijfers haalde ligt ver achter ons. Waarschijnlijk vinden jullie het schrijven van 
dit boekje hier nog wel een uiting van. Inmiddels zijn jullie succesvolle 
“zakenmannen” geworden en ben ik trots op jullie. Ik dank ook Magda en Henk 
voor de telkens weer warme ontvangst en voor de interesse, steun en hulp 
gedurende de afgelopen periode. En Yvonne… die halve marathon in Palma is 
afgesproken. Marieke en broertjes, doen jullie mee? 
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Lieve Bram, Hannah, Thijs en Lotte, het boekje van mama is af! Jullie 
vrolijkheid en stralende lach hebben gezorgd voor de nodige relativering zodat 
ik zeker niet uit het oog ben verloren dat er in het leven belangrijker zaken zijn 
dan het schrijven van een proefschrift.   
 
Liefste Bart, met name het afgelopen jaar was voor ons beiden ongelofelijk 
zwaar. Dankzij jou, mijn rots in de branding, heb ik het “overleefd”. Dank voor 
je onvoorwaardelijke steun en voor je enorme vertrouwen in mij. Dank dat je 
mijn datamanager was, mijn computerdokter en nog veel meer. Bedankt, 
gewoon voor alles! 
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Curriculum vitae 
Caroline Heijckmann werd op 3 mei 1967 geboren te Eindhoven. Na het 
behalen van het Gymnasium β diploma in 1985 aan het R.K. Gymnasium 
“Beekvliet” te Sint-Michielsgestel studeerde zij Geneeskunde aan de 
rijksuniversiteit Utrecht. Zij behaalde haar artsexamen in 1993, waarna zij als 
arts-assistent ging werken in het Diaconessenhuis Eindhoven. Een jaar later 
werd de overstap gemaakt naar het St. Elisabeth ziekenhuis te Tilburg, alwaar 
zij in 1996 startte met de opleiding tot internist (opleider dr. C. van der Heul). In 
2000 werd deze opleiding voortgezet in het Academisch Ziekenhuis Maastricht 
en werd tevens een start gemaakt met de opleiding in het aandachtsgebied 
endocrinologie (opleiders: prof. dr. H.F.P. Hillen (interne geneeskunde) en prof. 
dr. B.H.R. Wolffenbuttel (endocrinologie)). De registratie als internist-
endocrinoloog vond plaats in 2002. Vanaf 1 mei 2002 is zij werkzaam in 
ziekenhuis Bernhoven te Veghel en Oss. Gedurende de laatste jaren van haar 
opleiding en de vijf jaren daarna heeft zij gewerkt aan dit proefschrift. Zij is 
gehuwd met Bart-Jeroen Heesen en samen hebben zij vier kinderen: Bram 
(1999), Hannah (2001), Thijs (2006) en Lotte (2007). 
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